1
|
Leruez-Ville M, Chatzakis C, Lilleri D, Blazquez-Gamero D, Alarcon A, Bourgon N, Foulon I, Fourgeaud J, Gonce A, Jones CE, Klapper P, Krom A, Lazzarotto T, Lyall H, Paixao P, Papaevangelou V, Puchhammer E, Sourvinos G, Vallely P, Ville Y, Vossen A. Consensus recommendation for prenatal, neonatal and postnatal management of congenital cytomegalovirus infection from the European congenital infection initiative (ECCI). Lancet Reg Health Eur 2024; 40:100892. [PMID: 38590940 PMCID: PMC10999471 DOI: 10.1016/j.lanepe.2024.100892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Revised: 03/12/2024] [Accepted: 03/14/2024] [Indexed: 04/10/2024]
Abstract
Congenital cytomegalovirus (cCMV) infection carries a significant burden with a 0.64% global prevalence and a 17-20% chance of serious long-term effects in children. Since the last guidelines, our understanding, particularly regarding primary maternal infections, has improved. A cCMV guidelines group was convened under the patronage of the European Society of Clinical Virology in April 2023 to refine these insights. The quality and validity of selected studies were assessed for potential biases and the GRADE framework was employed to evaluate quality of evidence across key domains. The resulting recommendations address managing cCMV, spanning prevention to postnatal care. Emphasizing early and accurate maternal diagnosis through serological tests enhances risk management and prevention strategies, including using valaciclovir to prevent vertical transmission. The guidelines also strive to refine personalized postnatal care based on risk assessments, ensuring targeted interventions for affected families.
Collapse
Affiliation(s)
- Marianne Leruez-Ville
- Université Paris Cité, URP 7328 FETUS, F-75015, Paris, France
- Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections, Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France
| | - Christos Chatzakis
- Obstetrics, Fetal Medicine Surgery and Imaging Unit, Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France
- Second Department of Obstetrics and Gynecology of Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Daniele Lilleri
- Microbiology and Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Daniel Blazquez-Gamero
- Pediatric Infectious Diseases Unit, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Universidad Complutense, Madrid, Spain
| | - Ana Alarcon
- Department of Neonatology, Hospital Hospital Sant Joan de Déu, BCNatal (Barcelona Center for Maternal, Fetal and Neonatal Medicine), Institut de Recerca Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain
| | - Nicolas Bourgon
- Obstetrics, Fetal Medicine Surgery and Imaging Unit, Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France
| | - Ina Foulon
- Department of Otorhinolaryngology and Head & Neck Surgery, Vrije Universiteit Brussels, University Hospital UZ Brussel, Brussels Health Campus. De Poolster, Rehabilitation Centre, Brussels, Belgium
| | - Jacques Fourgeaud
- Université Paris Cité, URP 7328 FETUS, F-75015, Paris, France
- Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections, Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France
| | - Anna Gonce
- BCNatal: Fetal Medicine Research Center (Hospital Clínic and Hospital Sant Joan de Déu), Universitat de Barcelona, Barcelona, Spain
| | - Christine E. Jones
- Faculty of Medicine and Institute for Life Sciences, University of Southampton and NIHR Southampton Clinical Research Facility and NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, United Kingdom
| | - Paul Klapper
- Microbiology and Virology Unit (EIGen), School of Biological Sciences, University of Manchester, Manchester, M139PT, UK
| | - André Krom
- Department of Medical Ethics and Health Law, Leiden University Medical Center, Leiden, the Netherlands
| | - Tiziana Lazzarotto
- Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy
| | | | - Paulo Paixao
- CHRC, NOVA Medical School/Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, 1169-056, Lisbon, Portugal
| | - Vassiliki Papaevangelou
- Third Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Greece
| | | | - George Sourvinos
- Laboratory of Clinical Virology, Medical School, University of Crete, Heraklion, Crete, 71003, Greece
| | - Pamela Vallely
- Microbiology and Virology Unit (EIGen), School of Biological Sciences, University of Manchester, Manchester, M139PT, UK
| | - Yves Ville
- Université Paris Cité, URP 7328 FETUS, F-75015, Paris, France
- Obstetrics, Fetal Medicine Surgery and Imaging Unit, Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France
| | - Ann Vossen
- Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands
| |
Collapse
|
2
|
Fourgeaud J, Magny JF, Couderc S, Garcia P, Maillotte AM, Benard M, Pinquier D, Minodier P, Astruc D, Patural H, Parat S, Guillois B, Garenne A, Guilleminot T, Parodi M, Bussières L, Ghout I, Ville Y, Leruez-Ville M. Predictors of the Outcome at 2 Years in Neonates With Congenital Cytomegalovirus Infection. Pediatrics 2024; 153:e2023063531. [PMID: 38487823 DOI: 10.1542/peds.2023-063531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/05/2024] [Indexed: 04/02/2024] Open
Abstract
BACKGROUND Approximately 20% of neonates with congenital cytomegalovirus (cCMV) develop long-term sequelae. The ability to accurately predict long-term outcomes as early as the neonatal period would help to provide for appropriate parental counseling and treatment indications. With this study, we aimed to identify neonatal predictive markers of cCMV long-term outcomes. METHODS As this study's subjects, we chose neonates diagnosed with cCMV in 13 hospitals throughout France recruited from 2013 to 2017 and evaluated for at least 2 years with thorough clinical, audiology, and imaging evaluations and psychomotor development tests. RESULTS A total of 253 neonates were included, and 3 were later excluded because of the identification of a genetic disorder. A total of 227 were followed up for 2 years: 187/227 (82%) and 34/227 (15%) were infected after a maternal primary or nonprimary infection, respectively, 91/227 (40%) were symptomatic at birth, and 44/227 (19%) had cCMV sequelae. Maternal primary infection in the first trimester was the strongest prognosis factor (odds ratio = 38.34 [95% confidence interval, 5.02-293], P < .001). A predictive model of no risk of sequelae at 2 years of age according to normal hearing loss at birth, normal cerebral ultrasound, and normal platelet count had 98% specificity, 69% sensitivity, and 0.89 area under the curve (95% confidence interval, 0.83-0.96). CONCLUSIONS In the studied population, children with normal hearing at birth, normal platelet count at birth, and a normal cranial ultrasound had no risk of neurologic sequelae and a low risk of delayed unilateral sensorineural hearing loss. The use of this model based on readily available neonatal markers should help clinicians establish a personalized care pathway for each cCMV neonate.
Collapse
Affiliation(s)
- Jacques Fourgeaud
- URP 7328 FETUS, Université Paris Cité, Paris, France
- Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections
| | | | - Sophie Couderc
- Maternity, Hospital Intercommunal Poissy-Saint Germain, Poissy, France
| | - Patricia Garcia
- Neonatology and Intensive Care Department, AP-HM, Hospital La Conception, Marseille, France
| | | | - Melinda Benard
- Department of Neonatology, Toulouse University Hospital, Infinity, Université Toulouse, CNRS, Inserm, UPS, Toulouse, France
| | - Didier Pinquier
- Department of Neonatology, Rouen University Hospital, Rouen, France
| | | | - Dominique Astruc
- Department of Neonatology, Strasbourg University Hospital, Strasbourg, France
| | - Hugues Patural
- Department of Neonatology, Saint-Etienne, University Hospital, Saint-Etienne, France
| | - Sophie Parat
- Maternity, AP-HP, Hospital Cochin, Paris, France
| | - Bernard Guillois
- Department of Neonatology, CHU de Caen, Caen, France
- Université Caen Normandie Medical School, Caen, France
| | | | - Tiffany Guilleminot
- URP 7328 FETUS, Université Paris Cité, Paris, France
- Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections
| | | | - Laurence Bussières
- URP 7328 FETUS, Université Paris Cité, Paris, France
- Clinical Research Unit, P-HP
| | - Idir Ghout
- Cegedim Health Data, Boulogne-Billancourt, France
| | - Yves Ville
- URP 7328 FETUS, Université Paris Cité, Paris, France
- Maternity, AP-HP, Hôpital Necker Enfants Malades, Paris, France
| | - Marianne Leruez-Ville
- URP 7328 FETUS, Université Paris Cité, Paris, France
- Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections
| |
Collapse
|
3
|
Martin E, Winter S, Garcin C, Tanita K, Hoshino A, Lenoir C, Fournier B, Migaud M, Boutboul D, Simonin M, Fernandes A, Bastard P, Le Voyer T, Roupie AL, Ben Ahmed Y, Leruez-Ville M, Burgard M, Rao G, Ma CS, Masson C, Soudais C, Picard C, Bustamante J, Tangye SG, Cheikh N, Seppänen M, Puel A, Daly M, Casanova JL, Neven B, Fischer A, Latour S. Role of IL-27 in Epstein-Barr virus infection revealed by IL-27RA deficiency. Nature 2024; 628:620-629. [PMID: 38509369 DOI: 10.1038/s41586-024-07213-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Accepted: 02/20/2024] [Indexed: 03/22/2024]
Abstract
Epstein-Barr virus (EBV) infection can engender severe B cell lymphoproliferative diseases1,2. The primary infection is often asymptomatic or causes infectious mononucleosis (IM), a self-limiting lymphoproliferative disorder3. Selective vulnerability to EBV has been reported in association with inherited mutations impairing T cell immunity to EBV4. Here we report biallelic loss-of-function variants in IL27RA that underlie an acute and severe primary EBV infection with a nevertheless favourable outcome requiring a minimal treatment. One mutant allele (rs201107107) was enriched in the Finnish population (minor allele frequency = 0.0068) and carried a high risk of severe infectious mononucleosis when homozygous. IL27RA encodes the IL-27 receptor alpha subunit5,6. In the absence of IL-27RA, phosphorylation of STAT1 and STAT3 by IL-27 is abolished in T cells. In in vitro studies, IL-27 exerts a synergistic effect on T-cell-receptor-dependent T cell proliferation7 that is deficient in cells from the patients, leading to impaired expansion of potent anti-EBV effector cytotoxic CD8+ T cells. IL-27 is produced by EBV-infected B lymphocytes and an IL-27RA-IL-27 autocrine loop is required for the maintenance of EBV-transformed B cells. This potentially explains the eventual favourable outcome of the EBV-induced viral disease in patients with IL-27RA deficiency. Furthermore, we identified neutralizing anti-IL-27 autoantibodies in most individuals who developed sporadic infectious mononucleosis and chronic EBV infection. These results demonstrate the critical role of IL-27RA-IL-27 in immunity to EBV, but also the hijacking of this defence by EBV to promote the expansion of infected transformed B cells.
Collapse
Affiliation(s)
- Emmanuel Martin
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Sarah Winter
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
- Université Paris Cité, Paris, France
| | - Cécile Garcin
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
- Université Paris Cité, Paris, France
| | - Kay Tanita
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Akihiro Hoshino
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Christelle Lenoir
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Benjamin Fournier
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
- Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Mélanie Migaud
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France
| | - David Boutboul
- Université Paris Cité, Paris, France
- Department of Hematology, Cochin Hospital, AP-HP, Paris, France
| | - Mathieu Simonin
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Alicia Fernandes
- Plateforme Vecteurs Viraux et Transfert de Gènes, Institut Necker Enfants Malades, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - Paul Bastard
- Université Paris Cité, Paris, France
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Tom Le Voyer
- Université Paris Cité, Paris, France
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Anne-Laure Roupie
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
- Université Paris Cité, Paris, France
| | - Yassine Ben Ahmed
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
| | - Marianne Leruez-Ville
- Service de Bactériologie, Virologie, Parasitologie et Hygiène, Necker-Enfants Malades Hospital, Paris, France
| | - Marianne Burgard
- Service de Bactériologie, Virologie, Parasitologie et Hygiène, Necker-Enfants Malades Hospital, Paris, France
| | - Geetha Rao
- Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
| | - Cindy S Ma
- Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
- St Vincent's Clinical School, Faculty of Medicine and Health, Sydney, New South Wales, Australia
| | - Cécile Masson
- Plateforme de Bioinformatique, INSERM UMR1163, Université de Paris, Imagine Institute, Paris, France
| | - Claire Soudais
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
- Université Paris Cité, Paris, France
| | - Capucine Picard
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France
- Université Paris Cité, Paris, France
- Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, APHP, Paris, France
| | - Jacinta Bustamante
- Université Paris Cité, Paris, France
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France
- Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, APHP, Paris, France
- St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
| | - Stuart G Tangye
- Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
- St Vincent's Clinical School, Faculty of Medicine and Health, Sydney, New South Wales, Australia
| | - Nathalie Cheikh
- Hôpital Jean Minjoz, Centre Hospitalo-Universitaire de Besançon, Besançon, France
| | - Mikko Seppänen
- Pediatric Research Center and Rare Disease Center, New Children's Hospital, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland
| | - Anne Puel
- Université Paris Cité, Paris, France
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France
- St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
| | - Mark Daly
- Institut for Molecular Medecine Finland, University of Helsinki, Helsinki, Finland
| | - Jean-Laurent Casanova
- Université Paris Cité, Paris, France
- Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Imagine Institute, Paris, France
- St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
- Howard Hughes Medical Institute, New York, NY, USA
| | - Bénédicte Neven
- Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
| | - Alain Fischer
- Department of Pediatric Immunology, Hematology and Rheumatology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France
- Collège de France, Paris, France
- Imagine Institute, INSERM UMR 1163, Paris, France
| | - Sylvain Latour
- Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163, Imagine Institute, Paris, France.
- Université Paris Cité, Paris, France.
| |
Collapse
|
4
|
Vivanti AJ, Couffignal C, Sibiude J, Cordier AG, Tsatsaris V, Rozenberg F, Launay O, Benachi A, De Luca D, Ancel PY, Marcault E, Ville Y, Carrara J, Luton D, Dommergues M, Borie C, Kayem G, Lecomte L, Leruez-Ville M, Périllaud-Dubois C, Biran V, Manchon P, Picone O, Vauloup-Fellous C. Maternal and neonatal outcomes of French prospective multicenter cohort study COVIPREG during the first two COVID-19 waves. J Gynecol Obstet Hum Reprod 2024; 53:102764. [PMID: 38492667 DOI: 10.1016/j.jogoh.2024.102764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2024] [Revised: 03/04/2024] [Accepted: 03/05/2024] [Indexed: 03/18/2024]
Abstract
BACKGROUND SARS-CoV-2 infection on pregnant women was the subject of many questions since the COVID-19 pandemic. METHODS We aim to assess maternal and neonatal outcomes of SARS-CoV-2 infection contracted during 2nd and 3rd trimesters of pregnancy during the first two COVID-19 waves across a prospective French multicenter cohort study. Patients were included between April 2020 and January 2021 in 10 maternity hospitals in Paris area with two groups (i) pregnant women with a positive SARS-CoV-2 nasopharyngeal RT-PCR between [14WG; 37WG[(symptomatic infection), (ii) pregnant women with a negative serology (or equivocal) at delivery and without a positive SARS-CoV-2 nasopharyngeal RT-PCR at any time during pregnancy (G2 group) MAIN FINDINGS: 2410 pregnant women were included, of whom 310 had a positive SARS-CoV-2 nasopharyngeal RT-PCR and 217 between [14WG; 37WG[. Most infections occurred between 28 and 37 weeks of gestation (56 %). Most patients could be managed as outpatients, while 23 % had to be hospitalized. Among women with a positive RT-PCR, multiparous women were over-represented (OR = 2.45[1.52;3.87]); were more likely to deliver before 37 weeks of gestation (OR = 2.19[1.44;3.24]) and overall cesarean deliveries were significantly increased (OR = 1.53[1.09;2.13]). CONCLUSIONS This study highlights the maternal, obstetrical, and neonatal burden associated with SARS-CoV-2 infections during the first two pandemic waves before availability of vaccines. TRIAL REGISTRATION NCT04355234 (registration date: 21/04/2020).
Collapse
Affiliation(s)
- Alexandre J Vivanti
- Service de Gynécologie-Obstétrique, AP-HP, Hôpital Antoine Béclère, F-92140 Clamart, Université Paris-Saclay, Gif-sur-Yvette France; Groupe de Recherche sur les Infections Pendant la Grossesse (GRIG), Paris, France
| | - Camille Couffignal
- Université de Paris, F-75006 Paris, France; IAME U1137, Inserm, Université Paris Cité, Paris, France
| | - Jeanne Sibiude
- IAME U1137, Inserm, Université Paris Cité, Paris, France; Maternité, AP-HP, Hôpital Louis Mourier, F-75007 Paris, France
| | - Anne-Gael Cordier
- Groupe de Recherche sur les Infections Pendant la Grossesse (GRIG), Paris, France; Université Paris-Saclay, 91190 Gif-sur-Yvette, France; Maternité, AP-HP, Hôpital Bicêtre, F-94270 Le Kremlin-Bicêtre, France
| | - Vassilis Tsatsaris
- Service de Gynécologie-Obstétrique, AP-HP, Hôpital Cochin Port Royal, F-75007 Paris, France
| | - Flore Rozenberg
- Laboratoire de Virologie, AP-HP, Hôpital Cochin, F-75014 Paris, France
| | - Odile Launay
- CIC vaccinologie, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France
| | - Alexandra Benachi
- Service de Gynécologie-Obstétrique, AP-HP, Hôpital Antoine Béclère, F-92140 Clamart, Université Paris-Saclay, Gif-sur-Yvette France
| | - Daniele De Luca
- Réanimation néonatale, AP-HP, Hôpital Antoine Béclère, F-92140 Clamart, France
| | - Pierre-Yves Ancel
- Unité de recherche clinique, CIC-Mère enfant, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France
| | - Estelle Marcault
- Unité de recherche clinique PNVS, AP-HP, Hôpital Bichat, F-75018 Paris, France
| | - Yves Ville
- Maternité, AP-HP, Hôpital Necker, F-75007 Paris, France
| | - Julie Carrara
- Service de Gynécologie-Obstétrique, AP-HP, Hôpital Antoine Béclère, F-92140 Clamart, Université Paris-Saclay, Gif-sur-Yvette France
| | | | - Marc Dommergues
- Sorbonne Université, F-75006 Paris, France; Maternité, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France
| | - Constance Borie
- Maternité, AP-HP, Hôpital Robert Debré, F-75019 Paris, France
| | - Gilles Kayem
- Maternité, AP-HP, Hôpital Trousseau, F-75012 Paris, France
| | - Laurence Lecomte
- Unité de recherche clinique, CIC-Mère enfant, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France
| | | | - Claire Périllaud-Dubois
- IAME U1137, Inserm, Université Paris Cité, Paris, France; Université Paris-Saclay, INSERM U1193, 94804 Villejuif, France
| | - Valérie Biran
- Réanimation néonatale, AP-HP, Hôpital Robert Debré, F-75019 Paris, France
| | | | - Olivier Picone
- Groupe de Recherche sur les Infections Pendant la Grossesse (GRIG), Paris, France; IAME U1137, Inserm, Université Paris Cité, Paris, France; Maternité, AP-HP, Hôpital Louis Mourier, F-75007 Paris, France
| | - Christelle Vauloup-Fellous
- Groupe de Recherche sur les Infections Pendant la Grossesse (GRIG), Paris, France; Université Paris-Saclay, INSERM U1193, 94804 Villejuif, France; Laboratoire de Virologie, AP-HP, Hôpital Paul-Brousse, F-94804 Villejuif, France.
| |
Collapse
|
5
|
Materna M, Delmonte OM, Bosticardo M, Momenilandi M, Conrey PE, Muylder BCD, Bravetti C, Bellworthy R, Cederholm A, Staels F, Ganoza CA, Darko S, Sayed S, Le Floc’h C, Ogishi M, Rinchai D, Guenoun A, Bolze A, Khan T, Gervais A, Krüger R, Völler M, Palterer B, Sadeghi-Shabestari M, de Septenville AL, Schramm CA, Shah S, Tello-Cajiao JJ, Pala F, Amini K, Campos JS, Lima NS, Eriksson D, Lévy R, Seeleuthner Y, Jyonouchi S, Ata M, Al Ali F, Deswarte C, Pereira A, Mégre t J, Le Voyer T, Bastard P, Berteloot L, Dussiot M, Vladikine N, Cardenas PP, Jouanguy E, Alqahtani M, Hasan A, Thanaraj TA, Rosain J, Al Qureshah F, Sabato V, Alyanakian MA, Leruez-Ville M, Rozenberg F, Haddad E, Regueiro JR, Toribio ML, Kelsen JR, Salehi M, Nasiri S, Torabizadeh M, Rokni-Zadeh H, Changi-Ashtiani M, Vatandoost N, Moravej H, Akrami SM, Mazloomrezaei M, Cobat A, Meyts I, Etsushi T, Nishimura M, Moriya K, Mizukami T, Imai K, Abel L, Malissen B, Al-Mulla F, Alkuraya FS, Parvaneh N, von Bernuth H, Beetz C, Davi F, Douek DC, Cheynier R, Langlais D, Landegren N, Marr N, Morio T, Shahrooei M, Schrijvers R, Henrickson SE, Luche H, Notarangelo LD, Casanova JL, Béziat V. The immunopathological landscape of human pre-TCRα deficiency: From rare to common variants. Science 2024; 383:eadh4059. [PMID: 38422122 PMCID: PMC10958617 DOI: 10.1126/science.adh4059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Accepted: 01/26/2024] [Indexed: 03/02/2024]
Abstract
We describe humans with rare biallelic loss-of-function PTCRA variants impairing pre-α T cell receptor (pre-TCRα) expression. Low circulating naive αβ T cell counts at birth persisted over time, with normal memory αβ and high γδ T cell counts. Their TCRα repertoire was biased, which suggests that noncanonical thymic differentiation pathways can rescue αβ T cell development. Only a minority of these individuals were sick, with infection, lymphoproliferation, and/or autoimmunity. We also report that 1 in 4000 individuals from the Middle East and South Asia are homozygous for a common hypomorphic PTCRA variant. They had normal circulating naive αβ T cell counts but high γδ T cell counts. Although residual pre-TCRα expression drove the differentiation of more αβ T cells, autoimmune conditions were more frequent in these patients compared with the general population.
Collapse
Affiliation(s)
- Marie Materna
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
| | - Ottavia M. Delmonte
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
| | - Marita Bosticardo
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
| | - Mana Momenilandi
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
| | - Peyton E. Conrey
- Division of Allergy-Immunology, Department of Pediatrics, Children’s Hospital of Philadelphia; Philadelphia, USA
| | | | - Clotilde Bravetti
- Department of Biological Hematology, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP) and Sorbonne Université, Paris, France
- Sorbonne University, Paris Cancer Institute CURAMUS, INSERM U1138, Paris, France
| | - Rebecca Bellworthy
- Deptartment of Human Genetics, Dahdaleh Institute of Genomic Medicine, McGill University, Montreal, Quebec, Canada
| | - Axel Cederholm
- Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
| | - Frederik Staels
- Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium
| | | | - Samuel Darko
- Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Samir Sayed
- Division of Allergy-Immunology, Department of Pediatrics, Children’s Hospital of Philadelphia; Philadelphia, USA
| | - Corentin Le Floc’h
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
| | - Masato Ogishi
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA
| | - Darawan Rinchai
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA
| | | | | | - Taushif Khan
- Research Branch, Sidra Medicine, Doha, Qatar
- The Jackson Laboratory, Farmington, USA
| | - Adrian Gervais
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
| | - Renate Krüger
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
| | - Mirjam Völler
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
| | - Boaz Palterer
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
| | - Mahnaz Sadeghi-Shabestari
- Immunology Research Center, TB and Lung Disease Research Center, Mardaniazar children hospital, Tabriz University of Medical Science, Tabriz, Iran
| | - Anne Langlois de Septenville
- Department of Biological Hematology, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP) and Sorbonne Université, Paris, France
| | - Chaim A. Schramm
- Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Sanjana Shah
- Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - John J. Tello-Cajiao
- Division of Allergy-Immunology, Department of Pediatrics, Children’s Hospital of Philadelphia; Philadelphia, USA
- Department of Pathology, The Children’s Hospital of Philadelphia, Philadelphia, USA
| | - Francesca Pala
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
| | - Kayla Amini
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
| | - Jose S. Campos
- Division of Allergy-Immunology, Department of Pediatrics, Children’s Hospital of Philadelphia; Philadelphia, USA
| | - Noemia Santana Lima
- Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Daniel Eriksson
- Department of Immunology, Genetics and Pathology, Uppsala University and University Hospital, Section of Clinical Genetics, Uppsala, Sweden
| | - Romain Lévy
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
- Pediatric Immunology, Hematology and Rheumatology Unit, Necker Hospital for Sick Children, AP-HP, Paris, France
| | - Yoann Seeleuthner
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
| | - Soma Jyonouchi
- Division of Allergy-Immunology, Department of Pediatrics, Children’s Hospital of Philadelphia; Philadelphia, USA
| | - Manar Ata
- Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | | | - Caroline Deswarte
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
| | - Anaïs Pereira
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
| | - Jérôme Mégre t
- Cytometry Core Facility, SFR Necker, INSERM US24-CNRS UAR3633, Paris, France
| | - Tom Le Voyer
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
| | - Paul Bastard
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA
- Pediatric Immunology, Hematology and Rheumatology Unit, Necker Hospital for Sick Children, AP-HP, Paris, France
| | - Laureline Berteloot
- Department of Pediatric Radiology, University Hospital Necker-Enfants Malades, AP-HP, Paris, France
| | - Michaël Dussiot
- Imagine Institute, University of Paris-Cité, Paris, France
- Laboratory of Molecular Mechanisms of Hematological Disorders and Therapeutic Implications, INSERM UMR 1163, Paris, France
| | - Natasha Vladikine
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
| | - Paula P. Cardenas
- Department of Immunology, Complutense University School of Medicine and 12 de Octubre Health Research Institute (imas12), Madrid, Spain
| | - Emmanuelle Jouanguy
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA
| | - Mashael Alqahtani
- Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
| | - Amal Hasan
- Department of Translational Research, Research Division, Dasman Diabetes Institute, Dasman, Kuwait City, Kuwait
| | - Thangavel Alphonse Thanaraj
- Department of Genetics and Bioinformatics, Research Division, Dasman Diabetes Institute, Dasman, Kuwait City, Kuwait
| | - Jérémie Rosain
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
| | - Fahd Al Qureshah
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA
| | - Vito Sabato
- Department of Immunology, Allergology and Rheumatology, University of Antwerp, Antwerp University Hospital, Belgium
| | - Marie Alexandra Alyanakian
- Immunology Laboratory, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | | | - Flore Rozenberg
- University of Paris, Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France
- Virology, Cochin Hospital, AP-HP, APHP-CUP, Paris, France
| | - Elie Haddad
- Department of Pediatrics, Department of Microbiology, Immunology and Infectious Diseases, University of Montreal, CHU Sainte-Justine, Montreal, QC, Canada
| | - Jose R. Regueiro
- Department of Immunology, Complutense University School of Medicine and 12 de Octubre Health Research Institute (imas12), Madrid, Spain
| | - Maria L. Toribio
- Immune System Development and Function Unit, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain
| | - Judith R. Kelsen
- Division of Gastroenterology, Hepatology and Nutrition at Children's Hospital of Philadelphia
| | - Mansoor Salehi
- Cellular, Molecular and Genetics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
- Department of Genetics and Molecular Biology,Medical School, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Shahram Nasiri
- Department of Pediatric Neurology, Children's Medical Center of Abuzar, Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Mehdi Torabizadeh
- Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
| | - Hassan Rokni-Zadeh
- Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences (ZUMS), Zanjan, Iran
| | - Majid Changi-Ashtiani
- School of Mathematics, Institute for Research in Fundamental Sciences (IPM), Tehran, Iran
| | - Nasimeh Vatandoost
- Department of Genetics and Molecular Biology,Medical School, Isfahan University of Medical Sciences, Isfahan, Iran
- Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Hossein Moravej
- Neonatal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Seyed Mohammad Akrami
- Medical Genetics Poursina St., Genetic Deptartment, Medical Faculty, Tehran University of Medical Sciences, Tehran, Iran
- Dr. Shahrooei Laboratory, 22 Bahman St., Ashrafi Esfahani Blvd, Tehran, Iran
| | | | - Aurélie Cobat
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA
| | - Isabelle Meyts
- Laboratory for Inborn Errors of Immunity, Department of Microbiology, Immunology and Transplantation, Department of Pediatrics, University Hospitals Leuven, KU Leuven, Leuven, Belgium
- Department of Pediatrics, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Toyofuku Etsushi
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan
| | - Madoka Nishimura
- Department of Pediatrics, NHO Kumamoto Medical Center, Kumamoto, Japan
| | - Kunihiko Moriya
- Department of Pediatrics, National Defense Medical College, Saitama, Japan
| | - Tomoyuki Mizukami
- Department of Pediatrics, NHO Kumamoto Medical Center, Kumamoto, Japan
| | - Kohsuke Imai
- Department of Pediatrics, National Defense Medical College, Saitama, Japan
| | - Laurent Abel
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA
| | - Bernard Malissen
- Immunology Center of Marseille-Luminy, Aix Marseille University, Inserm, CNRS, Marseille, France
- Immunophenomics Center (CIPHE), Aix Marseille Université, Inserm, CNRS, Marseille, France
| | - Fahd Al-Mulla
- Department of Genetics and Bioinformatics, Research Division, Dasman Diabetes Institute, Dasman, Kuwait City, Kuwait
| | - Fowzan Sami Alkuraya
- Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
- Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
| | - Nima Parvaneh
- Division of Allergy and Clinical Immunology, Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran
| | - Horst von Bernuth
- Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany
- Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Germany
- Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Berlin, Germany
- Labor Berlin GmbH, Department of Immunology, Berlin, Germany
| | | | - Frédéric Davi
- Department of Biological Hematology, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP) and Sorbonne Université, Paris, France
- Sorbonne University, Paris Cancer Institute CURAMUS, INSERM U1138, Paris, France
| | - Daniel C. Douek
- Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Rémi Cheynier
- University of Paris, Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France
| | - David Langlais
- Deptartment of Human Genetics, Dahdaleh Institute of Genomic Medicine, McGill University, Montreal, Quebec, Canada
| | - Nils Landegren
- Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden
- Center for Molecular Medicine, Department of Medicine (Solna), Karolinska Institute, Stockholm, Sweden
| | - Nico Marr
- Department of Human Immunology, Sidra Medicine, Doha, Qatar
- College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
| | - Tomohiro Morio
- Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan
| | - Mohammad Shahrooei
- Dr. Shahrooei Laboratory, 22 Bahman St., Ashrafi Esfahani Blvd, Tehran, Iran
- Clinical and Diagnostic Immunology, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Belgium
| | - Rik Schrijvers
- Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium
| | - Sarah E. Henrickson
- Division of Allergy-Immunology, Department of Pediatrics, Children’s Hospital of Philadelphia; Philadelphia, USA
- Institute for Immunology and Immune Health, University of Pennsylvania; Philadelphia, USA
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania; Philadelphia, USA
| | - Hervé Luche
- Immunophenomics Center (CIPHE), Aix Marseille Université, Inserm, CNRS, Marseille, France
| | - Luigi D. Notarangelo
- Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA
| | - Jean-Laurent Casanova
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
- Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
- Department of Pediatrics, Necker Hospital for Sick Children, AP-HP, France
- Howard Hughes Medical Institute, The Rockefeller University, New York, USA
| | - Vivien Béziat
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM, Necker Hospital for Sick Children, Paris, France
- Imagine Institute, University of Paris-Cité, Paris, France
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, USA
| |
Collapse
|
6
|
Chatzakis C, Shahar-Nissan K, Faure-Bardon V, Picone O, Hadar E, Amir J, Egloff C, Vivanti A, Sotiriadis A, Leruez-Ville M, Ville Y. The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection, following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy. An individual patient data meta-analysis. Am J Obstet Gynecol 2024; 230:109-117.e2. [PMID: 37473793 DOI: 10.1016/j.ajog.2023.07.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 07/10/2023] [Accepted: 07/11/2023] [Indexed: 07/22/2023]
Abstract
OBJECTIVE Recent studies have shown that a dosage of 8 g/d of oral valacyclovir reduces substantially the vertical transmission rate of cytomegalovirus in women with primary cytomegalovirus infection acquired periconceptionally or during the first trimester of pregnancy. This individual patient data meta-analysis aimed to assess the effectiveness and safety of valacyclovir treatment in the secondary prevention of congenital cytomegalovirus infection. DATA SOURCES MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, the US registry of clinical trials (www. CLINICALTRIALS gov), and gray literature sources were searched from inception to March 2023. STUDY ELIGIBILITY CRITERIA Randomized controlled trials and quasi-randomized studies administering 8 g/d of oral valacyclovir in pregnant women with primary cytomegalovirus infection acquired periconceptionally or during the first trimester of pregnancy were included. METHODS All corresponding authors of the eligible studies were contacted. Cochrane's Risk of Bias 2 and Risk Of Bias In Non-randomised Studies - of Interventions tools were used for the risk of bias assessment. The result of amniocentesis was the primary outcome of interest. A 1-stage individual patient data meta-analysis was performed, using a generalized linear mixed model, clustered by the different trials. A subgroup analysis was performed, assessing separately the effect of valacyclovir in the periconceptional period and first trimester of pregnancy. RESULTS Overall, 3 studies were included in the analysis (n=527 women). Valacyclovir reduced the vertical transmission rate of cytomegalovirus (adjusted odds ratio, 0.34; 95% confidence interval, 0.18-0.61). This reduction was apparent for both periconceptional period (adjusted odds ratio, 0.34; 95% confidence interval, 0.12-0.96) and first-trimester (adjusted odds ratio, 0.35; 95% confidence interval, 0.16-0.76) infections. Moreover, valacyclovir reduced the rate of neonatal infection (adjusted odds ratio, 0.30; 95% confidence interval, 0.19-0.47), in both periconceptional period (adjusted odds ratio, 0.30; 95% confidence interval, 0.14-0.61) and first-trimester (adjusted odds ratio, 0.30; 95% confidence interval, 0.17-0.54) infections. Furthermore, valacyclovir reduced the rate of termination of pregnancy because of cytomegalovirus-associated severe fetal findings (adjusted odds ratio, 0.23; 95% confidence interval, 0.22-0.24). The gestational age at the initiation of treatment has a positive correlation with all outcomes. The overall prevalence of severe side effects was 2.1%. CONCLUSION A dosage of 8 g/d of oral valacyclovir reduced the vertical transmission rates of cytomegalovirus following primary maternal infection acquired periconceptionally or in the first trimester of pregnancy, with a low incidence of side effects.
Collapse
Affiliation(s)
- Christos Chatzakis
- Department of Obstetrics, Fetal-Medicine, and Surgery, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France; Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Karen Shahar-Nissan
- Department of Pediatrics "C," Schneider Children's Medical Center of Israel, Petach Tikvah, Israel; Sackler Faculty of Medicine, Department of Pediatric Infectious Diseases, Tel Aviv University, Tel Aviv, Israel
| | - Valentine Faure-Bardon
- Department of Obstetrics, Fetal-Medicine, and Surgery, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| | - Olivier Picone
- Department of Obstetrics and Gynecology, Hospital Paul Brousse, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| | - Eran Hadar
- Sackler Faculty of Medicine, Department of Pediatric Infectious Diseases, Tel Aviv University, Tel Aviv, Israel; Helen Schneider Hospital for Women, Rabin Medical Center, Petach Tikvah, Israel
| | - Jacob Amir
- Sackler Faculty of Medicine, Department of Pediatric Infectious Diseases, Tel Aviv University, Tel Aviv, Israel; Helen Schneider Hospital for Women, Rabin Medical Center, Petach Tikvah, Israel
| | - Charles Egloff
- Department of Obstetrics and Gynecology, Hospital Paul Brousse, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France
| | - Alexandre Vivanti
- Department of Obstetrics and Gynecology, DMU Santé des Femmes et des Nouveau-nés, Hôpital Antoine Béclère, Paris Saclay University, AP-HP, Clamart, France
| | - Alexandros Sotiriadis
- Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Marianne Leruez-Ville
- Virology Laboratory, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Yves Ville
- Department of Obstetrics, Fetal-Medicine, and Surgery, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France.
| |
Collapse
|
7
|
Fourgeaud J, Regnault B, Ok V, Da Rocha N, Sitterlé É, Mekouar M, Faury H, Milliancourt-Seels C, Jagorel F, Chrétien D, Bigot T, Troadec É, Marques I, Serris A, Seilhean D, Neven B, Frange P, Ferroni A, Lecuit M, Nassif X, Lortholary O, Leruez-Ville M, Pérot P, Eloit M, Jamet A. Performance of clinical metagenomics in France: a prospective observational study. Lancet Microbe 2024; 5:e52-e61. [PMID: 38048804 DOI: 10.1016/s2666-5247(23)00244-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 07/19/2023] [Accepted: 07/25/2023] [Indexed: 12/06/2023]
Abstract
BACKGROUND Metagenomic next-generation sequencing (mNGS) allows untargeted identification of a broad range of pathogens, including rare or novel microorganisms. Despite the recognition of mNGS as a valuable diagnostic tool for infections, the most relevant indications for this innovative strategy remain poorly defined. We aimed to assess the determinants of positivity and clinical utility of mNGS. METHODS In this observational study, we prospectively performed short-read shotgun metagenomics analysis as a second-line test (in cases of negative first-line test or when the symptoms were not fully explained by initial positive results) or as a first-line test in life-threatening situations requiring urgent non-targeted pathogen identification at the Necker-Enfants Malades Hospital (Paris, France). All sample types, clinical indications, and patient populations were included. Samples were accompanied by a mandatory form completed by the senior clinician or pathologist, on which the clinical level of suspected infection (defined as high or low) was indicated. We assessed the variables (gender, age, immune status, initial suspicion of infection, indication, and sample type) associated with mNGS pathogen detection using odds ratios (ORs) from multivariate logistic regression. Additional investigations were carried out using specific PCR or culture techniques, to confirm positive mNGS results, or when infectious suspicion was particularly high despite a negative mNGS result. FINDINGS Between Oct 29, 2019, and Nov 7, 2022, we analysed 742 samples collected from 523 patients. The initial suspicion of infection was either high (n=470, 63%) or low (n=272, 37%). Causative or possibly causative pathogens were detected in 117 (25%) samples from patients with high initial suspicion of infection, versus nine (3%) samples analysed to rule out infection (OR 9·1, 95% CI 4·6-20·4; p<0·0001). We showed that mNGS had higher odds of detecting a causative or possibly causative pathogenic virus on CNS biopsies than CSF samples (4·1, 1·7-10·7; p=0·0025) and in samples from immunodeficient compared with immunocompetent individuals (2·4, 1·4-4·1; p=0·0013). Concordance with conventional confirmatory tests results was 103 (97%) of 106, when mNGS detected causative or possibly causative pathogens. Altogether, among 231 samples investigated by both mNGS and subsequent specific tests, discordant results were found in 69 (30%) samples, of which 58 (84%) were mNGS positive and specific tests negative, and 11 (16%) mNGS negative and specific tests positive. INTERPRETATION Major determinants of pathogen detection by mNGS are immune status and initial level of suspicion of infection. These findings will contribute, along with future studies, to refining the positioning of mNGS in diagnostic and treatment decision-making algorithms. FUNDING Necker-Enfants Malades Hospital and Institut Pasteur. TRANSLATION For the French translation of the abstract see Supplementary Materials section.
Collapse
Affiliation(s)
- Jacques Fourgeaud
- Université Paris Cité, FETUS, Paris, France; Microbiology Department, AP-HP, Hôpital Necker, Paris, France
| | - Béatrice Regnault
- Institut Pasteur, Université Paris Cité, Pathogen Discovery Laboratory, Paris, France; Bioinformatics and Biostatistics Hub, Computational Biology Department, Institut Pasteur, Paris, France
| | - Vichita Ok
- Microbiology Department, AP-HP, Hôpital Necker, Paris, France
| | - Nicolas Da Rocha
- Institut Pasteur, Université Paris Cité, Pathogen Discovery Laboratory, Paris, France
| | - Émilie Sitterlé
- Microbiology Department, AP-HP, Hôpital Necker, Paris, France
| | - Meryem Mekouar
- Microbiology Department, AP-HP, Hôpital Necker, Paris, France
| | - Hélène Faury
- Microbiology Department, AP-HP, Hôpital Necker, Paris, France
| | | | - Florence Jagorel
- Institut Pasteur, Université Paris Cité, Pathogen Discovery Laboratory, Paris, France
| | - Delphine Chrétien
- Institut Pasteur, Université Paris Cité, Pathogen Discovery Laboratory, Paris, France
| | - Thomas Bigot
- Bioinformatics and Biostatistics Hub, Computational Biology Department, Institut Pasteur, Paris, France
| | - Éric Troadec
- Institut Pasteur, Université Paris Cité, Pathogen Discovery Laboratory, Paris, France
| | | | - Alexandra Serris
- Université Paris Cité, Centre d'Infectiologie Necker-Pasteur, IHU Imagine, Hôpital Necker, Paris, France
| | - Danielle Seilhean
- Département de Neuropathologie Raymond Escourolle, AP-HP-Sorbonne, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Institut du Cerveau-Paris Brain Institute-ICM, INSERM U1127, CNRS UMR7225, AP-HP, Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France
| | - Bénédicte Neven
- Pediatric Hematology Immunology and Rheumatology Unit, AP-HP, Hôpital Necker, Paris, France; Université Paris Cité, INSERM, Institut Imagine, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Paris, France
| | - Pierre Frange
- Université Paris Cité, FETUS, Paris, France; Microbiology Department, AP-HP, Hôpital Necker, Paris, France
| | - Agnès Ferroni
- Microbiology Department, AP-HP, Hôpital Necker, Paris, France
| | - Marc Lecuit
- Université Paris Cité, Centre d'Infectiologie Necker-Pasteur, IHU Imagine, Hôpital Necker, Paris, France; Institut Pasteur, Université de Paris, INSERM U1117, Biology of Infection Unit, Paris, France; Institut Pasteur, National Reference Center and WHO Collaborating Center Listeria, Paris, France
| | - Xavier Nassif
- Université Paris Cité, CNRS, INSERM, Institut Necker-Enfants Malades, Team Pathogenesis of Systemic Infection, Paris, France
| | - Olivier Lortholary
- Université Paris Cité, Centre d'Infectiologie Necker-Pasteur, IHU Imagine, Hôpital Necker, Paris, France; Institut Pasteur, Centre National de Référence Mycoses Invasives et Antifongiques, Département de Mycologie, Labex IBEID, Paris, France
| | - Marianne Leruez-Ville
- Université Paris Cité, FETUS, Paris, France; Microbiology Department, AP-HP, Hôpital Necker, Paris, France
| | - Philippe Pérot
- Institut Pasteur, Université Paris Cité, Pathogen Discovery Laboratory, Paris, France; Institut Pasteur, Centre National de Référence Mycoses Invasives et Antifongiques, Département de Mycologie, Labex IBEID, Paris, France
| | - Marc Eloit
- Institut Pasteur, Université Paris Cité, Pathogen Discovery Laboratory, Paris, France; Institut Pasteur, Université Paris Cité, The WOAH Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris, France; École Nationale Vétérinaire d'Alfort, Université Paris-Est, Maisons-Alfort, France
| | - Anne Jamet
- Microbiology Department, AP-HP, Hôpital Necker, Paris, France; Université Paris Cité, CNRS, INSERM, Institut Necker-Enfants Malades, Team Pathogenesis of Systemic Infection, Paris, France.
| |
Collapse
|
8
|
César T, Le MP, Klifa R, Castelle M, Fournier B, Lévy R, Chbihi M, Courteille V, Moshous D, Blanche S, Alligon M, Leruez-Ville M, Peytavin G, Frange P, Neven B. Letermovir for CMV Prophylaxis in Very High-Risk Pediatric Hematopoietic Stem Cell Transplantation Recipients for Inborn Errors of Immunity. J Clin Immunol 2023; 44:6. [PMID: 38117473 DOI: 10.1007/s10875-023-01617-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Accepted: 10/06/2023] [Indexed: 12/21/2023]
Abstract
The burden of CMV infection and disease is important in pediatric hematopoietic stem cell transplantation (HSCT), notably in the subgroup of patients with inborn errors of immunity (IEIs). Letermovir (LMV) is now a standard of care for CMV prophylaxis in adult sero-positive (R+) recipients, but is not yet labeled for children. Published pediatric studies are still scarce. We report a monocentric real-life use of LMV in 36 HSCT pediatric recipients with IEIs considered at high-risk of CMV infection including 14 patients between 2 and 12 months of age. A homogenous dosage proportional to the body surface area was used. Pharmacokinetic (PK) was performed in 8 patients with a median of 6 years of age (range 0,6;15). The cumulative incidence of clinically significant CMV infections (CS-CMVi) and the overall survival of patients under LMV were compared to a very similar historical cohort under (val)aciclovir prophylaxis. LMV tolerance was good. As compared to the historical cohort, the incidence of CS-CMVi was significantly lower in LMV group (5 out of 36 transplants (13.9%) versus 28 of the 62 HSCT (45.2%)) (p = 0.002). Plasma LMV exposures did not significantly differ with those reported in adult patients. In this high-risk pediatric HSCT cohort transplanted for IEIs, CMV prophylaxis with LMV at a homogenous dosage was well tolerated and effective in preventing CS-CMVi compared with a historical cohort.
Collapse
Affiliation(s)
- Thibaut César
- Pediatric Hematology-Immunology and Rheumatology Department, Assistance Publique Hôpitaux de Paris (APHP), Necker University Hospital, Paris, France
| | - Minh P Le
- Pharmacology Department, APHP, Bichat Hospital, Paris, France
- INSERM UMR_S 1144, Paris, France
| | - Roman Klifa
- Pediatric Hematology-Immunology and Rheumatology Department, Assistance Publique Hôpitaux de Paris (APHP), Necker University Hospital, Paris, France
- Université Paris Cité, Paris, France
| | - Martin Castelle
- Pediatric Hematology-Immunology and Rheumatology Department, Assistance Publique Hôpitaux de Paris (APHP), Necker University Hospital, Paris, France
| | - Benjamin Fournier
- Pediatric Hematology-Immunology and Rheumatology Department, Assistance Publique Hôpitaux de Paris (APHP), Necker University Hospital, Paris, France
- Université Paris Cité, Paris, France
- Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, INSERM UMR1163, Institut Imagine, Paris, France
| | - Romain Lévy
- Pediatric Hematology-Immunology and Rheumatology Department, Assistance Publique Hôpitaux de Paris (APHP), Necker University Hospital, Paris, France
- Université Paris Cité, Paris, France
- Laboratory of Human Genetics of Infectious Diseases, Inserm UMR 1163, Imagine Institute, Paris, France
| | - Marwa Chbihi
- Pediatric Hematology-Immunology and Rheumatology Department, Assistance Publique Hôpitaux de Paris (APHP), Necker University Hospital, Paris, France
- Université Paris Cité, Paris, France
| | - Virginie Courteille
- French reference center for primary immune deficiencies (CEREDIH), Necker University Hospital, APHP, Paris, France
| | - Despina Moshous
- Pediatric Hematology-Immunology and Rheumatology Department, Assistance Publique Hôpitaux de Paris (APHP), Necker University Hospital, Paris, France
- Université Paris Cité, Paris, France
- French reference center for primary immune deficiencies (CEREDIH), Necker University Hospital, APHP, Paris, France
- Laboratory of Genome Dynamics in the Immune System, Imagine Institute, INSERM UMR 1163, Paris, France
| | - Stéphane Blanche
- Pediatric Hematology-Immunology and Rheumatology Department, Assistance Publique Hôpitaux de Paris (APHP), Necker University Hospital, Paris, France
- Université Paris Cité, Paris, France
| | - Mickaël Alligon
- French reference center for primary immune deficiencies (CEREDIH), Necker University Hospital, APHP, Paris, France
| | - Marianne Leruez-Ville
- Laboratory of Clinical Microbiology, APHP, Necker University Hospital, & Université Paris Cité, Paris, 7328 FETUS, URP, France
| | - Gilles Peytavin
- Pharmacology Department, APHP, Bichat Hospital, Paris, France
- IAME, INSERM UMR 1137, Paris, France
| | - Pierre Frange
- Laboratory of Clinical Microbiology, APHP, Necker University Hospital, & Université Paris Cité, Paris, 7328 FETUS, URP, France
| | - Bénédicte Neven
- Pediatric Hematology-Immunology and Rheumatology Department, Assistance Publique Hôpitaux de Paris (APHP), Necker University Hospital, Paris, France.
- Université Paris Cité, Paris, France.
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Imagine Institute, INSERM UMR- S_1163, Paris, France.
| |
Collapse
|
9
|
Fourgeaud J, Nguyen CÂ, Guilleminot T, Ville Y, Leruez-Ville M. Comparison of two serological screening strategies for cytomegalovirus primary infection in the first trimester of pregnancy. J Clin Virol 2023; 169:105614. [PMID: 37982548 DOI: 10.1016/j.jcv.2023.105614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 10/20/2023] [Accepted: 10/22/2023] [Indexed: 11/21/2023]
Abstract
INTRODUCTION CMV serology screening in the first trimester pregnancy is based on IgG and IgM testing followed by IgG avidity in cases with positive IgM. However, the sensitivity of this strategy to diagnose maternal primary infection has been questioned. The objective of the study was to compare this strategy 1 with a strategy 2 consisting of running avidity test on all samples with positive IgG (ignoring IgM results) using fully automated current generation CMV IgG, IgM and IgG avidity assays. POPULATION AND METHODS 1516 consecutive pregnant women between 12 and 14 weeks were screened in one maternity. Strategy 1 was done prospectively with LIAISON® CMV IgG II and LIAISON® CMV IgM II, followed by LIAISON® CMV IgG Avidity II and VIDAS® CMV IgG avidity II testing in cases with positive or equivocal IgM. Strategy 2 was done retrospectively on the same population and consisted of running avidity with the LIAISON® CMV IgG Avidity II in all samples with positive IgG. RESULTS The sensitivity to diagnose a confirmed or a possible maternal primary infection in the first trimester was 91.6 % and 83 % for strategy 1 and 2 respectively (p > 0.99). Strategy 1 missed one possible primary infection and strategy 2 missed 2 confirmed primary infection. Inconclusive results happened in 0 and 0.7 % of samples with strategy 1 and 2 respectively. CONCLUSION This study suggests that strategy 1 has better sensitivity and practicability than strategy 2. However, to achieve a good performance with strategy 1, using highly sensitive IgM assay is mandatory.
Collapse
Affiliation(s)
- Jacques Fourgeaud
- Université Paris Cité, URP 7328 FETUS, F-75015, Paris, France; Virology Laboratory, Reference Laboratory for cytomegalovirus infections, AP-HP, Hôpital Necker Enfants Malades, F-75015, Paris, France.
| | - Chiêu-Ân Nguyen
- Virology Laboratory, Reference Laboratory for cytomegalovirus infections, AP-HP, Hôpital Necker Enfants Malades, F-75015, Paris, France
| | - Tiffany Guilleminot
- Virology Laboratory, Reference Laboratory for cytomegalovirus infections, AP-HP, Hôpital Necker Enfants Malades, F-75015, Paris, France
| | - Yves Ville
- Université Paris Cité, URP 7328 FETUS, F-75015, Paris, France; AP-HP, Hôpital Necker Enfants Malades, Maternity, Paris, 75015, France
| | - Marianne Leruez-Ville
- Université Paris Cité, URP 7328 FETUS, F-75015, Paris, France; Virology Laboratory, Reference Laboratory for cytomegalovirus infections, AP-HP, Hôpital Necker Enfants Malades, F-75015, Paris, France.
| |
Collapse
|
10
|
Nkobetchou M, Leruez-Ville M, Guilleminot T, Roux N, Petrilli G, Guimiot F, Saint-Frison MH, Deryabin I, Ville Y, Faure-Bardon V. SARS-CoV-2 infection as cause of in-utero fetal death: regional multicenter cohort study. Ultrasound Obstet Gynecol 2023; 62:867-874. [PMID: 37519281 DOI: 10.1002/uog.27439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 06/27/2023] [Accepted: 07/07/2023] [Indexed: 08/01/2023]
Abstract
OBJECTIVE Placental infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to placental insufficiency and in-utero fetal death (IUFD). The objective of this study was to confirm and quantify the extent to which fetoplacental infection with SARS-CoV-2 is a cause of fetal death. METHODS This was a multicenter retrospective cohort study of fetal deaths that underwent postmortem examination between January 2020 and January 2022 in three fetal pathology units in Paris, France. All cases of IUFD and termination of pregnancy (TOP) occurring in 31 maternity hospitals in the Paris region undergo detailed placental pathological examination in these units. Databases were searched for cases of IUFD and TOP. Cases with fetal malformation or cytogenetic abnormality were excluded to avoid bias. We included cases of IUFD with a placental or undetermined cause and cases of TOP in the context of severe intrauterine growth restriction (IUGR). Placentas were sent to a single virology unit for reverse-transcription polymerase chain reaction (RT-PCR) testing by a single laboratory technician blinded to the initial postmortem examination report. Our primary endpoint was the proportion of positive placental SARS-CoV-2 RT-PCR tests in the cohort. RESULTS Among 147 722 deliveries occurring over 2 years, 788 postmortem examinations for IUFD and TOP for severe IUGR were recorded, of which 462 (58.6%) were included. A total of 13/462 (2.8%) placentas tested positive for SARS-CoV-2 by RT-PCR. Wild-type virus and alpha and delta variants were identified. All positive cases had histological lesions consistent with placental dysfunction. There was a strong correlation between SARS-CoV-2 placentitis and the presence of chronic intervillositis and/or massive fibrin deposits in the placenta. When both lesion types were present, the specificity and negative predictive value for the diagnosis of placental SARS-CoV-2 infection were 0.99 (95% CI, 0.98-1.00) and 0.96 (95% CI, 0.94-0.98), respectively. CONCLUSIONS At the height of the SARS-CoV-2 pandemic, the cause of more than half of fetal deaths in the Paris area was determined by postmortem analysis to be of placental or undetermined origin. Of these cases, 2.8% were due to placental SARS-CoV-2 infection with a specific pattern of histological involvement. This study highlights the need for SARS-CoV-2 screening in stillbirth assessment. The impact of vaccination coverage remains to be established. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
Collapse
Affiliation(s)
- M Nkobetchou
- EA 73-28, Paris Cité University, Necker University Hospital, Paris, France
- Maternity Department, Necker University Hospital, Paris, France
| | - M Leruez-Ville
- EA 73-28, Paris Cité University, Necker University Hospital, Paris, France
- Virology Department, Necker University Hospital, Paris, France
| | - T Guilleminot
- EA 73-28, Paris Cité University, Necker University Hospital, Paris, France
- Virology Department, Necker University Hospital, Paris, France
| | - N Roux
- Histopathology Department, Necker University Hospital, Paris, France
| | - G Petrilli
- Histopathology Department, Necker University Hospital, Paris, France
| | - F Guimiot
- Histopathology Department, Robert Debré Hospital, Paris, France
| | | | - I Deryabin
- Histopathology Department, Trousseau Hospital, Paris, France
| | - Y Ville
- EA 73-28, Paris Cité University, Necker University Hospital, Paris, France
- Maternity Department, Necker University Hospital, Paris, France
| | - V Faure-Bardon
- EA 73-28, Paris Cité University, Necker University Hospital, Paris, France
- Maternity Department, Necker University Hospital, Paris, France
| |
Collapse
|
11
|
Fourgeaud J, Allali S, Toubiana J, Pinhas Y, Frange P, Leruez-Ville M, Cohen JF. Post-COVID-19 pandemic outbreak of severe Parvovirus B19 primary infections in Paris, France: 10-year interrupted time-series analysis (2012-2023). J Clin Virol 2023; 167:105576. [PMID: 37633184 DOI: 10.1016/j.jcv.2023.105576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Accepted: 08/21/2023] [Indexed: 08/28/2023]
Affiliation(s)
- Jacques Fourgeaud
- Microbiology department, Necker-Enfants malades Hospital, AP-HP, Université Paris Cité, Paris, France; Université Paris Cité, URP 7328 FETUS, Paris, France
| | - Slimane Allali
- Department of General Pediatrics and Pediatric Infectious Diseases, Necker-Enfants malades Hospital, AP-HP, Université Paris Cité, Paris, France; Sickle Cell Center, Necker-Enfants malades Hospital, AP-HP, Université Paris Cité, Paris, France
| | - Julie Toubiana
- Department of General Pediatrics and Pediatric Infectious Diseases, Necker-Enfants malades Hospital, AP-HP, Université Paris Cité, Paris, France
| | - Yael Pinhas
- Department of General Pediatrics and Pediatric Infectious Diseases, Necker-Enfants malades Hospital, AP-HP, Université Paris Cité, Paris, France
| | - Pierre Frange
- Microbiology department, Necker-Enfants malades Hospital, AP-HP, Université Paris Cité, Paris, France; Université Paris Cité, URP 7328 FETUS, Paris, France
| | - Marianne Leruez-Ville
- Microbiology department, Necker-Enfants malades Hospital, AP-HP, Université Paris Cité, Paris, France; Université Paris Cité, URP 7328 FETUS, Paris, France
| | - Jérémie F Cohen
- Department of General Pediatrics and Pediatric Infectious Diseases, Necker-Enfants malades Hospital, AP-HP, Université Paris Cité, Paris, France.
| |
Collapse
|
12
|
Fourgeaud J, Lecuit MM, Pérot P, Bruneau J, Regnault B, Da Rocha N, Bessaud M, Picard C, Jeziorski É, Fournier B, Levy R, Marçais A, Blanche S, Frange P, Fischer A, Cavazzana M, Ferroni A, Jamet A, Leruez-Ville M, Eloit M, Neven B. Chronic Aichi Virus Infection As a Cause of Long-Lasting Multiorgan Involvement in Patients With Primary Immune Deficiencies. Clin Infect Dis 2023; 77:620-628. [PMID: 37078608 DOI: 10.1093/cid/ciad237] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 04/08/2023] [Accepted: 04/14/2023] [Indexed: 04/21/2023] Open
Abstract
BACKGROUND Metagenomic next-generation sequencing (mNGS) was used to assess patients with primary or secondary immune deficiencies (PIDs and SIDs) who presented with immunopathological conditions related to immunodysregulation. METHODS Thirty patients with PIDs or SIDs who presented with symptoms related to immunodysregulation and 59 asymptomatic patients with similar PIDs or SIDs were enrolled. mNGS was performed on organ biopsy. Specific Aichi virus (AiV) reverse-transcription polymerase chain reaction (RT-PCR) was used to confirm AiV infection and screen the other patients. In situ hybridization (ISH) assay was done on AiV-infected organs to identify infected cells. Virus genotype was determined by phylogenetic analysis. RESULTS AiV sequences were detected using mNGS in tissue samples of 5 patients and by RT-PCR in peripheral samples of another patient, all of whom presented with PID and long-lasting multiorgan involvement, including hepatitis, splenomegaly, and nephritis in 4 patients. CD8+ T-cell infiltration was a hallmark of the disease. RT-PCR detected intermittent low viral loads in urine and plasma from infected patients but not from uninfected patients. Viral detection stopped after immune reconstitution obtained by hematopoietic stem cell transplantation. ISH demonstrated the presence of AiV RNA in hepatocytes (n = 1) and spleen tissue (n = 2). AiV belonged to genotype A (n = 2) or B (n = 3). CONCLUSIONS The similarity of the clinical presentation, the detection of AiV in a subgroup of patients suffering from immunodysregulation, the absence of AiV in asymptomatic patients, the detection of viral genome in infected organs by ISH, and the reversibility of symptoms after treatment argue for AiV causality.
Collapse
Affiliation(s)
- Jacques Fourgeaud
- Université Paris Cité, Fédération pour l'Étude et évaluation des Thérapeutiques intra-Utérines, Paris, France
- Microbiology Department, AP-HP, Hôpital Necker Paris, France
- Pathogen Discovery Laboratory, Institut Pasteur, Université Paris Cité, Paris, France
| | - Mathilde M Lecuit
- Pediatric Hematology Immunology and Rheumatology Unit, AP-HP, Hôpital Necker Paris, France
| | - Philippe Pérot
- Pathogen Discovery Laboratory, Institut Pasteur, Université Paris Cité, Paris, France
| | - Julie Bruneau
- Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, Université Paris Cité, Inserm, Institut Imagine Paris, France
- Department of Pathology, AP-HP, Hôpital Necker Paris, France
| | - Beatrice Regnault
- Pathogen Discovery Laboratory, Institut Pasteur, Université Paris Cité, Paris, France
| | - Nicolas Da Rocha
- Pathogen Discovery Laboratory, Institut Pasteur, Université Paris Cité, Paris, France
| | - Mael Bessaud
- Laboratoire signalisation antivirale, Institut Pasteur, Université Paris Cité, Paris, France
| | - Capucine Picard
- Laboratory of Lymphocyte Activation and Susceptibility to EBV Infection, Université Paris Cité, Inserm, Institut Imagine Paris, France
- Study Center for Primary Immunodeficiencies, Necker-Children's hospital, APHP Paris, France
| | - Éric Jeziorski
- Pediatric Hematology Immunology Unit, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Benjamin Fournier
- Pediatric Hematology Immunology and Rheumatology Unit, AP-HP, Hôpital Necker Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Université Paris Cité, Inserm, Institut Imagine Paris, France
| | - Romain Levy
- Pediatric Hematology Immunology and Rheumatology Unit, AP-HP, Hôpital Necker Paris, France
- Laboratory of Human Genetics of Infectious Diseases, Université Paris Cité, Inserm, Institut Imagine Paris, France
| | - Ambroise Marçais
- Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic Implications, Université Paris Cité, Inserm, Institut Imagine Paris, France
- Hepatology Unit, AP-HP, Hôpital Necker Paris, France
| | - Stéphane Blanche
- Pediatric Hematology Immunology and Rheumatology Unit, AP-HP, Hôpital Necker Paris, France
| | - Pierre Frange
- Université Paris Cité, Fédération pour l'Étude et évaluation des Thérapeutiques intra-Utérines, Paris, France
- Microbiology Department, AP-HP, Hôpital Necker Paris, France
| | - Alain Fischer
- Pediatric Hematology Immunology and Rheumatology Unit, AP-HP, Hôpital Necker Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Université Paris Cité, Inserm, Institut Imagine Paris, France
- Médecine expérimentale, Collège de France, Paris, France
| | - Marina Cavazzana
- Laboratory of Human Lympho-Hematopoiesis, Université Paris Cité, Inserm, Institut Imagine Paris, France
- Department of Biotherapy, Hôpital Necker, AP-HP Paris, France
| | - Agnès Ferroni
- Microbiology Department, AP-HP, Hôpital Necker Paris, France
| | - Anne Jamet
- Microbiology Department, AP-HP, Hôpital Necker Paris, France
- Department of Pathogenesis of systemic infections, Université Paris Cité, CNRS, Inserm, Institut Necker-Enfants Malades, Paris, France
| | - Marianne Leruez-Ville
- Université Paris Cité, Fédération pour l'Étude et évaluation des Thérapeutiques intra-Utérines, Paris, France
- Microbiology Department, AP-HP, Hôpital Necker Paris, France
| | - Marc Eloit
- Pathogen Discovery Laboratory, Institut Pasteur, Université Paris Cité, Paris, France
- Département des Sciences biologiques et Pharmaceutiques, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort, France
| | - Bénédicte Neven
- Pediatric Hematology Immunology and Rheumatology Unit, AP-HP, Hôpital Necker Paris, France
- Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Université Paris Cité, Inserm, Institut Imagine Paris, France
| |
Collapse
|
13
|
Uro-Coste C, Sberro-Soussan R, Martinez F, Amrouche L, Aubert O, Leruez-Ville M, Delage C, Peraldi MN, Legendre C, Lanternier F, Zuber J, Anglicheau D, Scemla A, Chavarot N. Immunogenicity of Anti-SARS-CoV-2 Vaccination After Kidney Transplantation in Kidney Transplant Recipients Vaccinated Before Transplantation. Transplantation 2023; 107:e213-e214. [PMID: 37211632 PMCID: PMC10358298 DOI: 10.1097/tp.0000000000004654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 03/28/2023] [Accepted: 03/28/2023] [Indexed: 05/23/2023]
Affiliation(s)
- Charlotte Uro-Coste
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Rebecca Sberro-Soussan
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris Cité, Paris, France
| | - Frank Martinez
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris Cité, Paris, France
| | - Lucile Amrouche
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris Cité, Paris, France
| | - Olivier Aubert
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris Cité, Paris, France
| | - Marianne Leruez-Ville
- Université Paris Cité, Paris, France
- Virology Laboratory, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Claire Delage
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marie Noëlle Peraldi
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris Cité, Paris, France
| | - Christophe Legendre
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris Cité, Paris, France
| | - Fanny Lanternier
- Université Paris Cité, Paris, France
- Department of infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Julien Zuber
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris Cité, Paris, France
| | - Dany Anglicheau
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris Cité, Paris, France
| | - Anne Scemla
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris Cité, Paris, France
| | - Nathalie Chavarot
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris Cité, Paris, France
| |
Collapse
|
14
|
Grapin M, Mirand A, Pinquier D, Basset A, Bendavid M, Bisseux M, Jeannoël M, Kireche B, Kossorotoff M, L'Honneur AS, Robin L, Ville Y, Renolleau S, Lemee V, Jarreau PH, Desguerre I, Lacaille F, Leruez-Ville M, Guillaume C, Henquell C, Lapillonne A, Schuffenecker I, Aubart M. Severe and fatal neonatal infections linked to a new variant of echovirus 11, France, July 2022 to April 2023. Euro Surveill 2023; 28:2300253. [PMID: 37261730 PMCID: PMC10236930 DOI: 10.2807/1560-7917.es.2023.28.22.2300253] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2023] [Accepted: 06/01/2023] [Indexed: 06/02/2023] Open
Abstract
We report nine severe neonatal infections caused by a new variant of echovirus 11. All were male, eight were twins. At illness onset, they were 3-5 days-old and had severe sepsis and liver failure. This new variant, detected in France since April 2022, is still circulating and has caused more fatal neonatal enterovirus infections in 2022 and 2023 (8/496; 1.6%, seven associated with echovirus 11) compared with 2016 to 2021 (7/1,774; 0.4%). National and international alerts are warranted.
Collapse
Affiliation(s)
- Mathilde Grapin
- Paediatric Intensive Care Unit, Necker-Enfants malades University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France
- These authors contributed equally to the work and share the first authorship
| | - Audrey Mirand
- These authors contributed equally to the work and share the first authorship
- Clermont-Ferrand University Hospital, 3IHP - Infection Inflammation et Interaction Hôtes Pathogènes Virology Department, French Reference Centre for enteroviruses and parechovirus, coordination laboratory, Clermont-Ferrand, France
- Auvergne University, LMGE UMR CNRS 6023, Team Epidemiology and pathophysiology of enterovirus Infection, Clermont-Ferrand, France
| | - Didier Pinquier
- Neonatal and Paediatric Intensive Care Units, Rouen University Hospital, Rouen, France
| | - Aurélie Basset
- Neonatal Intensive Care Unit, Cochin-Port Royal University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France
| | - Matthieu Bendavid
- Paediatric Intensive Care Unit, Necker-Enfants malades University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France
| | - Maxime Bisseux
- Clermont-Ferrand University Hospital, 3IHP - Infection Inflammation et Interaction Hôtes Pathogènes Virology Department, French Reference Centre for enteroviruses and parechovirus, coordination laboratory, Clermont-Ferrand, France
- Auvergne University, LMGE UMR CNRS 6023, Team Epidemiology and pathophysiology of enterovirus Infection, Clermont-Ferrand, France
| | - Marion Jeannoël
- Hospices Civils de Lyon, Virology Department, French Reference Centre for enteroviruses and parechoviruses, associated laboratory, Lyon, France
| | - Bérengère Kireche
- Neonatal and Paediatric Intensive Care Units, Orléans Regional Hospital, Orléans, France
| | - Manoelle Kossorotoff
- Paediatric Neurology Department, Necker-Enfants malades University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France
| | - Anne-Sophie L'Honneur
- Virology laboratory, Cochin University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France
| | - Lila Robin
- Neonatal and Paediatric Intensive Care Units, Orléans Regional Hospital, Orléans, France
| | - Yves Ville
- Obstetrics and Fetal Medicine Department, Necker-Enfants malades University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France
| | - Sylvain Renolleau
- Paediatric Intensive Care Unit, Necker-Enfants malades University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France
| | - Véronique Lemee
- Virology Department, Rouen University Hospital, Rouen, France
| | - Pierre-Henri Jarreau
- Neonatal Intensive Care Unit, Cochin-Port Royal University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France
| | - Isabelle Desguerre
- Paediatric Neurology Department, Necker-Enfants malades University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France
| | - Florence Lacaille
- Pediatric Gastroenterology-Hepatology-Nutrition Unit, Necker-Enfants malades University Hospital, Assistance Publique Hôpitaux de Paris, University of Paris, Paris, France
| | - Marianne Leruez-Ville
- Clinical Microbiology laboratory and Virology unit, Necker-Enfants malades University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France
| | | | - Cécile Henquell
- Clermont-Ferrand University Hospital, 3IHP - Infection Inflammation et Interaction Hôtes Pathogènes Virology Department, French Reference Centre for enteroviruses and parechovirus, coordination laboratory, Clermont-Ferrand, France
- Auvergne University, LMGE UMR CNRS 6023, Team Epidemiology and pathophysiology of enterovirus Infection, Clermont-Ferrand, France
| | - Alexandre Lapillonne
- Neonatal Intensive Care Unit, Necker-Enfants malades University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France
| | - Isabelle Schuffenecker
- These authors contributed equally to the work and share the last authorship
- Hospices Civils de Lyon, Virology Department, French Reference Centre for enteroviruses and parechoviruses, associated laboratory, Lyon, France
| | - Mélodie Aubart
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Imagine Institute, Institut National de la Santé et de la Recherche Médicale U1163, Paris, France
- These authors contributed equally to the work and share the last authorship
- Paediatric Neurology Department, Necker-Enfants malades University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France
| |
Collapse
|
15
|
Contejean A, Leruez-Ville M, Treluyer JM, Tsatsaris V, Ville Y, Charlier C, Chouchana L. Assessing the risk of adverse pregnancy outcomes and birth defects reporting in women exposed to ganciclovir or valganciclovir during pregnancy: a pharmacovigilance study. J Antimicrob Chemother 2023; 78:1265-1269. [PMID: 36964746 DOI: 10.1093/jac/dkad087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Accepted: 02/25/2023] [Indexed: 03/26/2023] Open
Abstract
OBJECTIVES Cytomegalovirus (CMV) is the leading cause of congenital infection worldwide. Reference anti-CMV treatment is valganciclovir/ganciclovir, which is contraindicated in pregnancy given questions about teratogenicity. METHODS We analysed reports from VigiBase, the world's largest safety database, and performed a disproportionality analysis of adverse pregnancy outcomes associated with (val)ganciclovir compared with any other drugs or with (val)aciclovir as comparators. RESULTS Among 3 104 984 reports related to childbearing-age women or to pregnancy topics, 6186 were exposed to (val)ganciclovir or (val)aciclovir including 251 adverse pregnancy outcomes with (val)ganciclovir (n = 34) or (val)aciclovir (n = 217). We did not evidence any increased reporting of any adverse pregnancy outcome [miscarriage, stillbirth, small weight for gestational age, preterm birth (<37 weeks of gestation)] or birth defects with (val)ganciclovir compared with the use of (val)aciclovir during pregnancy. Four cases of oesophageal and anorectal atresia were identified with (val)ganciclovir, which may be related to concomitant drugs/medical conditions and require further analyses. CONCLUSIONS These preliminary results require confirmation but suggest the possibility for trial evaluation of val(ganciclovir) in severe maternal or fetal CMV infections.
Collapse
Affiliation(s)
- Adrien Contejean
- Université Paris Cité, Paris, France
- Infectious Diseases Department, Cochin Port Royal University Hospital, AP-HP Centre, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
| | - Marianne Leruez-Ville
- Microbiology Unit, Necker-Enfants Malades University Hospital, AP-HP Centre, Paris, France
- Université Paris Cité, Imagine, FETUS, F-75015 Paris, France
| | - Jean-Marc Treluyer
- Université Paris Cité, Paris, France
- Regional Center of Pharmacovigilance, Pharmacology Department, Cochin Port Royal University Hospital, AP-HP Centre, Paris, France
- Research Team EA7323 "Pharmacology and Therapeutic Assessment in Children and Pregnant Women", Université Paris Cité, Paris, France
| | - Vassilis Tsatsaris
- Université Paris Cité, Paris, France
- Obstetrical Department, Cochin Port Royal University Hospital, AP-HP Centre, Paris, France
| | - Yves Ville
- Université Paris Cité, Paris, France
- Obstetrical Department, Necker Enfants Malades University Hospital, AP-HP Centre, Paris, France
- Université Paris Cité, Imagine, FETUS, F-75015 Paris, France
| | - Caroline Charlier
- Université Paris Cité, Paris, France
- Infectious Diseases Department, Cochin Port Royal University Hospital, AP-HP Centre, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
- Institut Pasteur, French National Reference Center and WHO Collaborating Center Listeria, Paris, France
- Institut Pasteur, Biology of Infection Unit, Inserm U1117, Paris, France
| | - Laurent Chouchana
- Regional Center of Pharmacovigilance, Pharmacology Department, Cochin Port Royal University Hospital, AP-HP Centre, Paris, France
- Research Team EA7323 "Pharmacology and Therapeutic Assessment in Children and Pregnant Women", Université Paris Cité, Paris, France
| |
Collapse
|
16
|
Fourgeaud J, Magny JF, Couderc S, Garcia P, Maillotte AM, Benard M, Pinquier D, Minodier P, Astruc D, Patural H, Ugolin M, Parat S, Guillois B, Garenne A, Guilleminot T, Parodi M, Bussières L, Ville Y, Leruez-Ville M. Clinical Value of Serial Quantitative Analysis of Cytomegalovirus DNA in Blood and Saliva Over the First 24 Months of Life in Congenital Infection: The French Cymepedia Cohort. J Pediatr 2023; 253:197-204.e5. [PMID: 36181870 DOI: 10.1016/j.jpeds.2022.09.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 09/21/2022] [Accepted: 09/23/2022] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To evaluate cytomegalovirus (CMV) viral load dynamics in blood and saliva during the first 2 years of life in symptomatic and asymptomatic infected infants and to identify whether these kinetics could have practical clinical implications. STUDY DESIGN The Cymepedia cohort prospectively included 256 congenitally infected neonates followed for 2 years. Whole blood and saliva were collected at inclusion and months 4 and 12, and saliva at months 18 and 24. Real-time CMV polymerase chain reaction (PCR) was performed, results expressed as log10 IU/mL in blood and in copies per milliliter in saliva. RESULTS Viral load in saliva progressively decreased from 7.5 log10 at birth to 3.3 log10 at month 24. CMV PCR in saliva was positive in 100% and 96% of infants at 6 and 12 months, respectively. In the first month of life, neonatal saliva viral load of less than 5 log10 was related to a late CMV transplacental passage. Detection in blood was positive in 92% of neonates (147/159) in the first month of life. No viral load threshold values in blood or saliva could be associated with a high risk of sequelae. Neonatal blood viral load of less than 3 log10 IU/mL had a 100% negative predictive value for long-term sequelae. CONCLUSIONS Viral loads in blood and saliva by CMV PCR testing in congenital infection fall over the first 24 months. In this study of infants affected mainly after primary maternal infection during pregnancy, all salivary samples were positive in the first 6 months of life and sequelae were not seen in infants with neonatal blood viral load of less than 3 log10 IU/mL.
Collapse
Affiliation(s)
- Jacques Fourgeaud
- Research Unit 73-28, Université Paris Cité, Paris, France; Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections, AP-HP, Hôpital Necker Enfants Malades, Paris, France.
| | - Jean-François Magny
- Research Unit 73-28, Université Paris Cité, Paris, France; Neonatal Intensive Care Unit, AP-HP, Hôpital Necker Enfants Malades, Paris, France
| | - Sophie Couderc
- Maternity, Hospital Intercommunal Poissy-Saint Germain, Poissy, France
| | - Patricia Garcia
- Neonatology and Intensive Care Department, AP-HM, Hospital La Conception, Marseille, France
| | | | - Melinda Benard
- Department of Neonatalogy, Toulouse University Hospital, Toulouse, France
| | - Didier Pinquier
- Department of Neonatology, Rouen University Hospital, Rouen, France
| | | | - Dominique Astruc
- Department of Neonatology, Strasbourg University Hospital, Strasbourg, France
| | - Hugues Patural
- Neonatal Intensive Care Unit, University Hospital, Saint-Etienne, France
| | - Melissa Ugolin
- Pediatric Department, Neonatology, CHU Rennes and CIC1414, Rennes, France
| | - Sophie Parat
- Maternity, AP-HP, Hospital Cochin, Paris, France
| | - Bernard Guillois
- Department of Neonatalogy, CHU de Caen, Caen, France; Medical School, Université Caen Normandie, Caen, France
| | - Armelle Garenne
- Neonatal and Pediatric Intensive Care Unit, CHRU Brest, Brest, France
| | - Tiffany Guilleminot
- Research Unit 73-28, Université Paris Cité, Paris, France; Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections, AP-HP, Hôpital Necker Enfants Malades, Paris, France
| | - Marine Parodi
- Otology Department, AP-HP, Hôpital Necker Enfants Malades, Paris, France
| | - Laurence Bussières
- Research Unit 73-28, Université Paris Cité, Paris, France; Clinical Research Unit, AP-HP, Hôpital Necker Enfants Malades, Paris, France
| | - Yves Ville
- Research Unit 73-28, Université Paris Cité, Paris, France; Maternity, AP-HP, Hôpital Necker Enfants Malades, Paris, France
| | - Marianne Leruez-Ville
- Research Unit 73-28, Université Paris Cité, Paris, France; Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections, AP-HP, Hôpital Necker Enfants Malades, Paris, France
| |
Collapse
|
17
|
Pérot P, Fourgeaud J, Rouzaud C, Regnault B, Da Rocha N, Fontaine H, Le Pavec J, Dolidon S, Garzaro M, Chrétien D, Morcrette G, Molina TJ, Ferroni A, Leruez-Ville M, Lortholary O, Jamet A, Eloit M. Circovirus Hepatitis Infection in Heart-Lung Transplant Patient, France. Emerg Infect Dis 2023; 29:286-293. [PMID: 36596569 PMCID: PMC9881760 DOI: 10.3201/eid2902.221468] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
In March 2022, a 61-year-old woman in France who had received a heart-lung transplant sought treatment with chronic hepatitis mainly characterized by increased liver enzymes. After ruling out common etiologies, we used metagenomic next-generation sequencing to analyze a liver biopsy sample and identified an unknown species of circovirus, tentatively named human circovirus 1 (HCirV-1). We found no other viral or bacterial sequences. HCirV-1 shared 70% amino acid identity with the closest known viral sequences. The viral genome was undetectable in blood samples from 2017-2019, then became detectable at low levels in September 2020 and peaked at very high titers (1010 genome copies/mL) in January 2022. In March 2022, we found >108 genome copies/g or mL in the liver and blood, concomitant with hepatic cytolysis. We detected HCirV-1 transcripts in 2% of hepatocytes, demonstrating viral replication and supporting the role of HCirV-1 in liver damage.
Collapse
Affiliation(s)
| | | | | | - Béatrice Regnault
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Nicolas Da Rocha
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Hélène Fontaine
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Jérôme Le Pavec
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Samuel Dolidon
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Margaux Garzaro
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Delphine Chrétien
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Guillaume Morcrette
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Thierry Jo Molina
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Agnès Ferroni
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | - Marianne Leruez-Ville
- Institut Pasteur Pathogen Discovery Laboratory, Paris, France (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- The OIE Collaborating Center for the Detection and Identification in Humans of Emerging Animal Pathogens, Paris (P. Pérot, B. Regnault, N. Da Rocha, D. Chrétien, M. Eloit)
- Institut Imagine, Paris (J. Fourgeaud, M. Leruez-Ville); Université Paris Cité, Paris (J. Fourgeaud, A. Jamet)
- Necker-Enfants Malades Hospital, Paris (J. Fourgeaud, G. Morcrette, T.J. Molina, A. Ferroni, M. Leruez-Ville, A. Jamet)
- Hôpital Necker Enfants-Malades Centre d'Infectiologie Necker-Pasteur, Paris (C. Rouzaud, M. Garzaro, O. Lortholary)
- Groupe Hospitalier Paris Saint Joseph-Marie Lannelongue, Équipe Mobile de Microbiologie Clinique, Paris (C. Rouzaud)
- Hôpital Cochin Département d'Hépatologie-Addictologie, Paris (H. Fontaine)
- Université Paris–Sud, Paris (J. Le Pavec)
- Hôpital Marie Lannelongue Service de Pneumologie et Transplantation Pulmonaire, Le Plessis-Robinson, France (J. Le Pavec, S. Dolidon)
- Institut Necker Enfants Malades, Paris (A. Jamet)
- Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France (M. Eloit)
| | | | | | | |
Collapse
|
18
|
Fourgeaud J, Regnault B, Faury H, Da Rocha N, Jamet A, Stirnemann J, Eloit M, Perot P, Leruez-Ville M, Driessen M. Fetal Zika virus infection diagnosed by metagenomic next-generation sequencing of amniotic fluid. Ultrasound Obstet Gynecol 2023; 61:116-117. [PMID: 36102858 DOI: 10.1002/uog.26074] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Revised: 08/22/2022] [Accepted: 09/02/2022] [Indexed: 05/27/2023]
Affiliation(s)
- J Fourgeaud
- Université Paris Cité, FETUS, Paris, France
- Department of Clinical Microbiology, Necker-Enfants Malades Hospital, AP-HP, Paris, France
| | - B Regnault
- Pathogen Discovery Laboratory, Institut Pasteur, Université de Paris, Paris, France
| | - H Faury
- Department of Clinical Microbiology, Necker-Enfants Malades Hospital, AP-HP, Paris, France
| | - N Da Rocha
- Pathogen Discovery Laboratory, Institut Pasteur, Université de Paris, Paris, France
| | - A Jamet
- Université Paris Cité, FETUS, Paris, France
- Department of Clinical Microbiology, Necker-Enfants Malades Hospital, AP-HP, Paris, France
- Institut Necker-Enfants Malades, INSERM U1151, CNRS UMR, 8253, Paris, France
| | - J Stirnemann
- Université Paris Cité, FETUS, Paris, France
- Department of Obstetrics and Fetal Therapy, Necker-Enfants Malades Hospital, AP-HP, Paris, France
| | - M Eloit
- Pathogen Discovery Laboratory, Institut Pasteur, Université de Paris, Paris, France
| | - P Perot
- Pathogen Discovery Laboratory, Institut Pasteur, Université de Paris, Paris, France
| | - M Leruez-Ville
- Université Paris Cité, FETUS, Paris, France
- Department of Clinical Microbiology, Necker-Enfants Malades Hospital, AP-HP, Paris, France
| | - M Driessen
- Department of Obstetrics and Fetal Therapy, Necker-Enfants Malades Hospital, AP-HP, Paris, France
| |
Collapse
|
19
|
Sichitiu J, Bourgon N, Guilleminot T, Bessieres B, Leruez-Ville M, Ville Y. Third trimester placentitis: an underreported complication of SARS-CoV-2 infection. Am J Obstet Gynecol MFM 2022; 4:100703. [PMID: 35931366 PMCID: PMC9345653 DOI: 10.1016/j.ajogmf.2022.100703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 07/13/2022] [Accepted: 07/28/2022] [Indexed: 11/16/2022]
Abstract
SARS-CoV-2-related placentitis shows distinctive histologic characteristics, and its impact on perinatal outcomes is increasingly under scrutiny. We present two such cases in the third trimester displaying mild maternal clinical symptoms and associated with maternal coagulopathy, reduced fetal movements, and nonreassuring fetal heart rate tracing. Both cases resulted in emergency cesarean deliveries. Our cases and a review of the literature highlight that SARS-CoV-2 undermines placental function and thus greatly impacts late-term pregnancies, even in the absence of severe systemic disease.
Collapse
Affiliation(s)
- Joanna Sichitiu
- Department of Obstetrics and Maternal-Fetal Medicine, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France (Drs Sichitiu, Bourgon, and Ville).
| | - Nicolas Bourgon
- Department of Obstetrics and Maternal-Fetal Medicine, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France (Drs Sichitiu, Bourgon, and Ville); University of Paris - EHU 7328, Paris University, Paris, France (Dr Bourgon, Ms Guilleminot, and Drs Bessieres, Leruez-Ville, and Ville)
| | - Tiffany Guilleminot
- University of Paris - EHU 7328, Paris University, Paris, France (Dr Bourgon, Ms Guilleminot, and Drs Bessieres, Leruez-Ville, and Ville); Virology Laboratory, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France (Ms Guilleminot and Dr Leruez-Ville)
| | - Bettina Bessieres
- University of Paris - EHU 7328, Paris University, Paris, France (Dr Bourgon, Ms Guilleminot, and Drs Bessieres, Leruez-Ville, and Ville); Department of Histology, Embryology and Cytogenetics, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France (Dr Bessieres)
| | - Marianne Leruez-Ville
- University of Paris - EHU 7328, Paris University, Paris, France (Dr Bourgon, Ms Guilleminot, and Drs Bessieres, Leruez-Ville, and Ville); Virology Laboratory, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France (Ms Guilleminot and Dr Leruez-Ville)
| | - Yves Ville
- Department of Obstetrics and Maternal-Fetal Medicine, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France (Drs Sichitiu, Bourgon, and Ville); University of Paris - EHU 7328, Paris University, Paris, France (Dr Bourgon, Ms Guilleminot, and Drs Bessieres, Leruez-Ville, and Ville)
| |
Collapse
|
20
|
Fourgeaud J, Toubiana J, Chappuy H, Delacourt C, Moulin F, Parize P, Scemla A, Abid H, Leruez-Ville M, Frange P. No durable impact of COVID-19 measures on the hospital burden of Respiratory Syncytial Virus (France, 2018-2022). J Infect 2022; 85:436-480. [PMID: 35760301 PMCID: PMC9233884 DOI: 10.1016/j.jinf.2022.06.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Revised: 06/13/2022] [Accepted: 06/20/2022] [Indexed: 11/18/2022]
Affiliation(s)
- Jacques Fourgeaud
- Laboratoire de microbiologie clinique, Hopital Necker - Enfants malades, Groupe hospitalier Assistance Publique - Hôpitaux de Paris (AP-HP).Centre - Université Paris Cité, Paris, France.; EHU 7327, Institut Imagine, Université de Paris, Paris, France.; CNR Cytomegalovirus, Laboratoire associé, Hôpital Necker-Enfants malades, Paris, France
| | - Julie Toubiana
- Service de Pédiatrie générale et Maladies infectieuses, Hôpital Necker - Enfants malades, Groupe hospitalier AP-HP.Centre - Université Paris Cité, Paris, France.; CNR de la Coqueluche et autres Bordetelloses, Unité « Biodiversité et épidémiologie des bactéries pathogènes », Institut Pasteur, Paris, France
| | - Hélène Chappuy
- Service d'Urgences pédiatriques, Hôpital Necker - Enfants malades, Groupe hospitalier AP-HP.Centre - Université Paris Cité, Paris, France.; EA7323, Université Paris Cité, Paris, France
| | - Christophe Delacourt
- Service de pneumologie et allergologie pédiatriques, Hôpital Necker - Enfants malades, Groupe hospitalier AP-HP.Centre - Université Paris Cité, Paris, France
| | - Florence Moulin
- Service de Réanimation et surveillance continue médico-chirurgicale pédiatrique, Hôpital Necker Enfants-Malades, Groupe hospitalier AP-HP.Centre - Université Université Paris Cité, Paris, France
| | - Perrine Parize
- Service de Maladies infectieuses et tropicales, Hôpital Necker - Enfants malades, Groupe hospitalier AP-HP.Centre -Université Paris Cité, Paris. France
| | - Anne Scemla
- Service de Néphrologie - Transplantation, Hôpital Necker-Enfants malades, Groupe hospitalier AP-HP.Centre - Université Paris Cité, Paris, France.; RTRS Centaure, Labex Transplantex, Université Paris Cité, France
| | - Hanene Abid
- Laboratoire de microbiologie clinique, Hopital Necker - Enfants malades, Groupe hospitalier Assistance Publique - Hôpitaux de Paris (AP-HP).Centre - Université Paris Cité, Paris, France
| | - Marianne Leruez-Ville
- Laboratoire de microbiologie clinique, Hopital Necker - Enfants malades, Groupe hospitalier Assistance Publique - Hôpitaux de Paris (AP-HP).Centre - Université Paris Cité, Paris, France.; EHU 7327, Institut Imagine, Université de Paris, Paris, France.; CNR Cytomegalovirus, Laboratoire associé, Hôpital Necker-Enfants malades, Paris, France
| | - Pierre Frange
- Laboratoire de microbiologie clinique, Hopital Necker - Enfants malades, Groupe hospitalier Assistance Publique - Hôpitaux de Paris (AP-HP).Centre - Université Paris Cité, Paris, France.; EHU 7327, Institut Imagine, Université de Paris, Paris, France..
| |
Collapse
|
21
|
Fourgeaud J, Boithias C, Walter-Nicolet E, Kermorvant E, Couderc S, Parat S, Pol C, Mousset C, Bussières L, Guilleminot T, Ville Y, Nkam L, Grimaldi L, Parodi M, Leruez-Ville M. Performance of Targeted Congenital Cytomegalovirus Screening in Newborns Failing Universal Hearing Screening: A Multicenter Study. Pediatr Infect Dis J 2022; 41:478-481. [PMID: 35093998 DOI: 10.1097/inf.0000000000003474] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Cytomegalovirus (CMV) is the most frequent cause of congenital infection and ≈20% of all infected neonates present or will develop sensorineural hearing loss. Targeted congenital CMV (cCMV) screening in newborns who failed universal newborn hearing screening has been proposed as a strategy to identify neonates with both hearing loss and cCMV infection who could benefit from antiviral treatment implemented within the first month of life. OBJECTIVES To evaluate the feasibility and performance of cCMV targeted screening in a French setting. METHODS Neonates were recruited in 5 maternity centers in greater Paris. A saliva sample for CMV polymerase chain reaction (PCR) testing was collected in neonates who failed newborn hearing screening. Outcomes including CMV PCR result and confirmation of hearing loss by an otorhinolaryngologist specialist were documented. RESULTS Two-hundred thirty-six newborns were included and a saliva sample was collected in 98% (231/236) of them. The result of CMV PCR was available at a median of 9 days (7-10 days) of life and in 96% of cases within the first month of life. Two neonates were infected with CMV. The result of the otorhinolaryngologist assessment was available in 75% (178/236) of cases at a median of 16 days (9-26 days). Hearing loss was confirmed in 2.8% (5/178). The 2 infected neonates had hearing loss confirmed at 5 and 8 days of life and were treated with valganciclovir at days 9 and 16, respectively. CONCLUSIONS The result of this study confirms that targeted cCMV screening is feasible in these French settings.
Collapse
Affiliation(s)
- Jacques Fourgeaud
- From the EA 73-28, Université de Paris
- AP-HP, Hospital Necker-E.M., Virology Department, Reference Laboratory for Cytomegalovirus Infections, Paris, France
| | - Claire Boithias
- AP-HP, Hospital Bicêtre, Neonatal Intensive Care Unit, Le Kremlin-Bicêtre, France
| | - Elisabeth Walter-Nicolet
- INSERM, U1153, Epidemiology and Statistics Sorbonne Paris Cité Research Center; and Medicine and Neonatal Intensive Care Unit, Groupe Hospitalier Paris Saint Joseph, Paris, France
| | - Elsa Kermorvant
- AP-HP, Hospital Necker-E.M., Neonatal Intensive Care Unit, Université de Paris, Paris, France
| | - Sophie Couderc
- Hospital Intercommunal Poissy-Saint Germain, Maternity, Poissy, France
| | - Sophie Parat
- AP-HP, Hospital Cochin, Maternity, Paris, France
| | - Christine Pol
- AP-HP, Hospital Bicêtre, Otology Department, Le Kremlin-Bicêtre, France
| | - Carole Mousset
- Hospital Saint Joseph, Otology Department, Paris, France
| | - Laurence Bussières
- From the EA 73-28, Université de Paris
- AP-HP, Hospital Necker-E.M., Clinical Research Unit
| | - Tiffany Guilleminot
- From the EA 73-28, Université de Paris
- AP-HP, Hospital Necker-E.M., Virology Department, Reference Laboratory for Cytomegalovirus Infections, Paris, France
| | - Yves Ville
- From the EA 73-28, Université de Paris
- AP-HP, Hospital Necker-E.M., Maternity
| | - Lionelle Nkam
- AP-HP, Hôpital Ambroise Paré, Unité de Recherche Clinique, Paris Saclay Ouest, Boulogne, France
| | - Lamiae Grimaldi
- AP-HP, Hôpital Ambroise Paré, Unité de Recherche Clinique, Paris Saclay Ouest, Boulogne, France
| | - Marine Parodi
- AP-HP, Hospital Necker-E.M, Otology Department, Paris, France
| | - Marianne Leruez-Ville
- From the EA 73-28, Université de Paris
- AP-HP, Hospital Necker-E.M., Virology Department, Reference Laboratory for Cytomegalovirus Infections, Paris, France
| |
Collapse
|
22
|
Chavarot N, Melenotte C, Amrouche L, Rouzaud C, Sberro-Soussan R, Pavie J, Martinez F, Pouvaret A, Leruez-Ville M, Cantin D, Fourgeaud J, Delage C, Vimpere D, Peraldi MN, Legendre C, Lanternier F, Zuber J, Scemla A, Anglicheau D. Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection. Kidney Int 2022; 101:1290-1293. [PMID: 35421508 PMCID: PMC9001009 DOI: 10.1016/j.kint.2022.04.003] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Revised: 03/16/2022] [Accepted: 04/05/2022] [Indexed: 02/05/2023]
Affiliation(s)
- Nathalie Chavarot
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
| | - Clea Melenotte
- Université de Paris, Paris, France; Department of infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Lucile Amrouche
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Claire Rouzaud
- Université de Paris, Paris, France; Department of infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Rebecca Sberro-Soussan
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Juliette Pavie
- Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, Paris, France
| | - Frank Martinez
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Anne Pouvaret
- Université de Paris, Paris, France; Department of infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marianne Leruez-Ville
- Université de Paris, Paris, France; Virology Laboratory, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Delphine Cantin
- COVID-19 screening center, Emergency Department, Hôtel Dieu Hospital, Assistance Publique-Hôpitaux de Paris, France
| | - Jacques Fourgeaud
- Université de Paris, Paris, France; Virology Laboratory, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Claire Delage
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Damien Vimpere
- Adult Intensive Care Unit, Department of Anaesthesiology, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marie Noëlle Peraldi
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Christophe Legendre
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Fanny Lanternier
- Université de Paris, Paris, France; Department of infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Julien Zuber
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Anne Scemla
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Dany Anglicheau
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| |
Collapse
|
23
|
Drummond D, Thumerelle C, Roux A, Mordacq C, Frange P, Leruez-Ville M, Gibault L, Berteloot L, Roy C, Pontailler M, Lopez V, Oualha M, Grimaud M, de Saint Blanquat L, Parquin F, Sermet-Gaudelus I. Severe COVID-19 evolving towards organizing pneumonia in a pediatric lung transplant recipient. Pediatr Pulmonol 2022; 57:583-585. [PMID: 34727580 PMCID: PMC8662090 DOI: 10.1002/ppul.25744] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Accepted: 10/25/2021] [Indexed: 12/01/2022]
Affiliation(s)
- David Drummond
- Department of Pediatric Pulmonology and Allergology, Necker-Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France.,Faculté de médecine, Université de Paris, Paris, France
| | - Caroline Thumerelle
- Department of Pediatric Pulmonology, Jeanne de Flandre Hospital, Lille, France
| | - Antoine Roux
- Department of Pediatric Pulmonology and Allergology, Necker-Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France.,Department of Respiratory Medicine, Foch Hospital, Suresnes, France
| | - Clémence Mordacq
- Department of Pediatric Pulmonology, Jeanne de Flandre Hospital, Lille, France
| | - Pierre Frange
- Faculté de médecine, Université de Paris, Paris, France.,Department of Clinical Microbiology, Necker-Enfants Malades University Hospital, APHP, Paris, France
| | - Marianne Leruez-Ville
- Faculté de médecine, Université de Paris, Paris, France.,Department of Clinical Microbiology, Necker-Enfants Malades University Hospital, APHP, Paris, France
| | - Laure Gibault
- Department of Pathology, George Pompidou European Hospital, APHP, Paris, France
| | - Laureline Berteloot
- Department of Pediatric Radiology, Necker-Enfants Malades University Hospital, APHP, Paris, France
| | - Charlotte Roy
- Department of Pediatric Pulmonology and Allergology, Necker-Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France.,Faculté de médecine, Université de Paris, Paris, France
| | - Margaux Pontailler
- Faculté de médecine, Université de Paris, Paris, France.,Department of Pediatric Cardiac Surgery, Necker-Enfants Malades University Hospital, APHP, Paris, France
| | - Vanessa Lopez
- Department of Pediatric Cardiac Surgery, Necker-Enfants Malades University Hospital, APHP, Paris, France
| | - Mehdi Oualha
- Faculté de médecine, Université de Paris, Paris, France.,Pediatric Intensive Care Unit, Necker-Enfants Malades University Hospital, APHP, Paris, France
| | - Marion Grimaud
- Pediatric Intensive Care Unit, Necker-Enfants Malades University Hospital, APHP, Paris, France
| | - Laure de Saint Blanquat
- Pediatric Intensive Care Unit, Necker-Enfants Malades University Hospital, APHP, Paris, France
| | - François Parquin
- Department of Respiratory Medicine, Foch Hospital, Suresnes, France
| | - Isabelle Sermet-Gaudelus
- Department of Pediatric Pulmonology and Allergology, Necker-Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (APHP), Paris, France.,Faculté de médecine, Université de Paris, Paris, France.,Equipe "Canalopathies épitheliales: Mucoviscidose et autres maladies", INSERM U1151, Necker Institute, Paris, France
| |
Collapse
|
24
|
Mizrahi A, Nguyen Van JC, El Helali N, Lourtet-Hascoet J, Jabnoune I, Pacreau ML, Talb Y, Fourgeaud J, Leruez-Ville M, Pilmis B, Avettand-Fenoel V, Le Monnier A. The Coris BioConcept COVID 19 Ag Respi-Strip, a field experience feedback. J Virol Methods 2022; 300:114366. [PMID: 34801594 PMCID: PMC8600801 DOI: 10.1016/j.jviromet.2021.114366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2020] [Revised: 08/02/2021] [Accepted: 11/17/2021] [Indexed: 11/09/2022]
Abstract
This communication described how the Coris BioConcept COVID-19 Ag Respi-Strip test (Coris-Ag) was implemented in the workflow of our clinical microbiology laboratory for COVID-19 diagnosis. The diagnostic performance statistics (sensitivity, specificity) of the Coris-Ag were evaluated against a gold standard, the RealStar SARS-CoV-2 RT-PCR kit 1.0. Additionally, the effect of reading the Coris-Ag results at 30 min was compared to reading at 15 min. The Coris-Ag was performed on a total of 294 patients during two periods; 158 patients were tested during period 1 at the peak of the pandemic (April 6th to April 10th 2020) which returned a positivity rate of 17.1 %, and 136 patients during period 2 (April 12th to April 16th 2020) which returned a positivity rate of 11 %. Compared to the RT-PCR, the 15-minute Coris-Ag readings resulted in a sensitivity of 59.3 % with a 100 % specificity for the period 1 patients (n = 158) while the sensitivity decreased to 20 % for the period 2 patients (n = 136). The overall sensitivity was 38.1 % for both periods (n = 294). The corresponding 30-minute readings produced a 7 % increase in sensitivity with a specificity of 100 % (n = 294). The sensitivity of the strip test (15-min reading) for high viral loads (Ct <25) was 84.6 %.
Collapse
Affiliation(s)
- Assaf Mizrahi
- Service de Microbiologie clinique, Groupe hospitalier Paris Saint Joseph, Paris, France; Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France.
| | | | - Najoua El Helali
- Service de Microbiologie clinique, Groupe hospitalier Paris Saint Joseph, Paris, France
| | - Julie Lourtet-Hascoet
- Service de Microbiologie clinique, Groupe hospitalier Paris Saint Joseph, Paris, France
| | - Ines Jabnoune
- Service de Microbiologie clinique, Groupe hospitalier Paris Saint Joseph, Paris, France
| | - Marie Liesse Pacreau
- Service de Microbiologie clinique, Groupe hospitalier Paris Saint Joseph, Paris, France
| | - Yasmina Talb
- Service de Microbiologie clinique, Groupe hospitalier Paris Saint Joseph, Paris, France
| | - Jacques Fourgeaud
- Service de Microbiologie clinique, Hôpital Universitaire Necker - Enfants Malades, AP-HP, Paris, France,EA7328, Université de Paris, Paris, France
| | - Marianne Leruez-Ville
- Service de Microbiologie clinique, Hôpital Universitaire Necker - Enfants Malades, AP-HP, Paris, France,EA7328, Université de Paris, Paris, France
| | - Benoît Pilmis
- Service de Microbiologie clinique, Groupe hospitalier Paris Saint Joseph, Paris, France,Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France
| | - Véronique Avettand-Fenoel
- Service de Microbiologie clinique, Hôpital Universitaire Necker - Enfants Malades, AP-HP, Paris, France,Université de Paris, CNRS 8104, INSERM U1016, Paris, France
| | - Alban Le Monnier
- Service de Microbiologie clinique, Groupe hospitalier Paris Saint Joseph, Paris, France,Institut Micalis UMR 1319, Université Paris-Saclay, INRAe, AgroParisTech, Châtenay Malabry, France
| |
Collapse
|
25
|
Chimon A, Ferrière E, Lammouchi MA, Jouan N, Michel PA, Saloum K, Morand-Joubert L, Schnuriger A, Leruez-Ville M, Fourgeaud J, Dahmane D, Bentaarit B, Guéry B, Fessi H, Kazdaghli H, Sounni F, Fearon T, Boudhabhay I, Pawlotsky JM, El Karoui K, Fourati S, Sakhi H. OUP accepted manuscript. Clin Kidney J 2022; 15:1785-1788. [PMID: 35999965 PMCID: PMC9383950 DOI: 10.1093/ckj/sfac137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Indexed: 11/17/2022] Open
Affiliation(s)
| | | | | | | | | | - Kenda Saloum
- Virology Department, Trousseau Hospital, APHP, Sorbonne University, Paris, France
| | | | - Aurélie Schnuriger
- Virology Department, Trousseau Hospital, APHP, Sorbonne University, Paris, France
| | | | - Jacques Fourgeaud
- Virology Department, Necker Hospital, APHP, University of Paris, Paris, France
| | - Djamal Dahmane
- Nephrology Department, Mondor Hospital, APHP, University Paris Est, Créteil, France
| | - Boutheina Bentaarit
- Nephrology Department, Mondor Hospital, APHP, University Paris Est, Créteil, France
| | - Bruno Guéry
- Nephrology Department, Necker Hospital, APHP, University of Paris, Paris, France
| | - Hafedh Fessi
- Nephrology Department, Tenon Hospital, APHP, Sorbonne University, Paris, France
| | - Hajer Kazdaghli
- Nephrology Department, Tenon Hospital, APHP, Sorbonne University, Paris, France
| | - Farah Sounni
- Nephrology Department, Tenon Hospital, APHP, Sorbonne University, Paris, France
| | - Timothée Fearon
- Nephrology Department, Tenon Hospital, APHP, Sorbonne University, Paris, France
| | - Idris Boudhabhay
- Nephrology Department, Necker Hospital, APHP, University of Paris, Paris, France
| | | | | | | | | |
Collapse
|
26
|
Chavarot N, Morel A, Leruez-Ville M, Vilain E, Divard G, Burger C, Serris A, Sberro-Soussan R, Martinez F, Amrouche L, Bererhi L, Lanternier F, Legendre C, Zuber J, Anglicheau D, Scemla A. Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept. Am J Transplant 2021; 21:4043-4051. [PMID: 34431207 PMCID: PMC9906354 DOI: 10.1111/ajt.16814] [Citation(s) in RCA: 69] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Revised: 08/16/2021] [Accepted: 08/17/2021] [Indexed: 01/25/2023]
Abstract
Poor responses to mRNA COVID-19 vaccine have been reported after 2 vaccine injections in kidney transplant recipients (KTRs) treated with belatacept. We analyzed the humoral response in belatacept-treated KTRs without a history of SARS-CoV-2 infection who received three injections of BNT162b2-mRNA COVID-19 vaccine. We also investigated vaccine immunogenicity in belatacept-treated KTRs with prior COVID-19 and characterized symptomatic COVID-19 infections after the vaccine in belatacept-treated KTRs. Among the 62 belatacept-treated KTRs (36 [58%] males), the median age (63.5 years IQR [51-72]), without COVID-19 history, only four patients (6.4%) developed anti-SARS-CoV-2 IgG with low antibody titers (median 209, IQR [20-409] AU/ml). 71% were treated with mycophenolic acid and 100% with steroids in association with belatacept. In contrast, in all the 5 KTRs with prior COVID-19 history, mRNA vaccine induced a strong antibody response with high antibody titers (median 10 769 AU/ml, IQR [6410-20 069]) after two injections. Seroprevalence after three-vaccine doses in 35 non-belatacept-treated KTRs was 37.1%. Twelve KTRs developed symptomatic COVID-19 after vaccination, including severe forms (50% of mortality). Breakthrough COVID-19 occurred in 5% of fully vaccinated patients. Administration of a third dose of BNT162b2 mRNA COVID-19 vaccine did not improve immunogenicity in KTRs treated with belatacept without prior COVID-19. Other strategies aiming to improve patient protection are needed.
Collapse
Affiliation(s)
- Nathalie Chavarot
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Antoine Morel
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marianne Leruez-Ville
- Université de Paris, Paris, France
- Virology Laboratory, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Estelle Vilain
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Gillian Divard
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Carole Burger
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Alexandra Serris
- Université de Paris, Paris, France
- Department of Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Rebecca Sberro-Soussan
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Frank Martinez
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Lucile Amrouche
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Lynda Bererhi
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Fanny Lanternier
- Université de Paris, Paris, France
- Department of Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Christophe Legendre
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Julien Zuber
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Dany Anglicheau
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Anne Scemla
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| |
Collapse
|
27
|
Seror V, Leruez-Ville M, Ӧzek A, Ville Y. Leaning towards Cytomegalovirus serological screening in pregnancy to prevent congenital infection: a cost-effectiveness perspective. BJOG 2021; 129:301-312. [PMID: 34651405 DOI: 10.1111/1471-0528.16966] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2021] [Revised: 09/24/2021] [Accepted: 10/07/2021] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To assess the cost-effectiveness of prenatal detection of congenital cytomegalovirus (cCMV) following maternal primary infection in the first trimester within standard pregnancy follow-up or involving population-based screening (serological testing at 7 and 12 weeks of gestation), with or without secondary prevention (valaciclovir) in maternal CMV primary infection. DESIGN Cost-effectiveness study from the perspective of the French national health insurance system. SETTING Cost-effectiveness based on previously published probability estimates and associated plausible ranges hypothetical population of 1,000,000 pregnant women. POPULATION Hypothetical population of 1,000,000 pregnant women. METHODS Cost-effectiveness of detecting fetal cCMV in terms of the total direct medical costs involved and associated expected outcomes. MAIN OUTCOME MEASURES Detection rates and clinical outcomes at birth. RESULTS Moving to a population-based approach for targeting fetal CMV infections would generate high monetary and organizational costs while increasing detection rates from 15% to 94%. This resource allocation would help implementing horizontal equity according to which individuals with similar medical needs should be treated equally. Secondary prevention with valaciclovir had a significant effect on maternal-fetal CMV transmission and clinical outcomes in newborns, with a 58% decrease of severely infected newborns for a 3.5% additional total costs. Accounting for women decision-making (amniocentesis uptake and termination of pregnancy in severe cases) did not impact the cost-effectiveness results. CONCLUSIONS These findings could fuel thinking on the opportunity of developing clinical guidelines to rule identification of cCMV infection and administration of in-utero treatment. These findings could fuel the development of clinical guidelines on the identification of congenital CMV infection and the administration of treatment in utero. TWEETABLE ABSTRACT CMV serological screening followed by valaciclovir prevention may prevent 58% to 71% of severe cCMV cases for 38 € per pregnancy.
Collapse
Affiliation(s)
- V Seror
- Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.,Institut Hospitalier Universitaire (IHU) - Méditerranée Infection, Marseille, France
| | - M Leruez-Ville
- Virology Laboratory, Hôpital Necker-Enfants Malades, AP-HP, National Reference Centre for Herpesviridae, Paris, France.,EA7328, Institut Imagine, Université de Paris, Paris, France
| | - A Ӧzek
- EA7328, Institut Imagine, Université de Paris, Paris, France.,Maternity, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
| | - Y Ville
- EA7328, Institut Imagine, Université de Paris, Paris, France.,Maternity, Hôpital Necker-Enfants Malades, AP-HP, Paris, France
| |
Collapse
|
28
|
Faure-Bardon V, Fourgeaud J, Stirnemann J, Leruez-Ville M, Ville Y. Secondary prevention of congenital cytomegalovirus infection with valacyclovir following maternal primary infection in early pregnancy. Ultrasound Obstet Gynecol 2021; 58:576-581. [PMID: 33998084 DOI: 10.1002/uog.23685] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Revised: 05/05/2021] [Accepted: 05/06/2021] [Indexed: 06/12/2023]
Abstract
OBJECTIVE Cytomegalovirus (CMV) maternal primary infection (MPI) in early pregnancy is the main risk factor for congenital CMV (cCMV) infection with long-term sequelae. Our aim was to evaluate, in a single center offering CMV serology screening at 11-14 gestational weeks, secondary prevention of cCMV by administration of high-dosage maternal oral valacyclovir (VACV) in the first trimester of pregnancy. METHODS This was a case-control study in a longitudinal cohort of pregnancies with CMV-MPI diagnosed prior to 14 weeks of gestation by serology screening (immunoglobulin (Ig) M and IgG measurement and IgG avidity) between 2009 and 2020. From October 2019 onwards, all women presenting at our center with MPI before 14 weeks' gestation were offered treatment with high-dosage oral VACV (8 g/day, 4 g twice/day). We used propensity score matching to compare fetal infection rates in cases treated with maternal oral VACV (8 g/day) with those in untreated controls. Fetal infection was assessed following amniocentesis at 17-22 weeks of gestation, by polymerase chain reaction (PCR) analysis of amniotic fluid for viral DNA. RESULTS Of 310 cases of CMV-MPI identified, 269 underwent amniocentesis for PCR. Of these, 66 were offered, and 65 accepted, treatment with VACV. From the remaining untreated cases, we selected 65 controls, matched for proportion of periconceptional infections and gestational age at amniocentesis. VACV was initiated at a median gestational age of 12.71 (interquartile range (IQR), 10.00-13.86) weeks and the median duration of treatment was 35 (IQR, 26-54) days. On multivariate logistic regression, fetal infection was lower in the treated group (odds ratio, 0.318 (95% CI, 0.120-0.841); P = 0.021). One treated patient developed acute renal failure 4 weeks after initiation of VACV therapy, but this resolved within 5 days after treatment was stopped. CONCLUSION This study confirms the acceptability, tolerance and benefit of secondary prevention by VACV of cCMV infection in a clinical setting with a well-established routine maternal serum screening policy in the first trimester of pregnancy. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
Collapse
Affiliation(s)
- V Faure-Bardon
- Obstetrics and Fetal Medicine Department, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
- EA7328, Institut Hospitalo-Universitaire Imagine, Paris, France
| | - J Fourgeaud
- Université de Paris, Paris, France
- EA7328, Institut Hospitalo-Universitaire Imagine, Paris, France
- Virology Laboratory, Associated with the National Herpes Viridae Reference Laboratory, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
| | - J Stirnemann
- Obstetrics and Fetal Medicine Department, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
- EA7328, Institut Hospitalo-Universitaire Imagine, Paris, France
| | - M Leruez-Ville
- Université de Paris, Paris, France
- EA7328, Institut Hospitalo-Universitaire Imagine, Paris, France
- Virology Laboratory, Associated with the National Herpes Viridae Reference Laboratory, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Y Ville
- Obstetrics and Fetal Medicine Department, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
- EA7328, Institut Hospitalo-Universitaire Imagine, Paris, France
| |
Collapse
|
29
|
Ville Y, Leruez-Ville M. Renal toxicity of high-dosage valacyclovir for secondary prevention of congenital cytomegalovirus infection: a dose regimen-related issue. Ultrasound Obstet Gynecol 2021; 58:637-638. [PMID: 34468055 DOI: 10.1002/uog.24753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Revised: 08/18/2021] [Accepted: 08/19/2021] [Indexed: 06/13/2023]
Affiliation(s)
- Y Ville
- EA7328, Université de Paris & Institut IMAGINE, Paris, France
- Department of Obstetrics, Fetal Medicine and Surgery and Fetal Imaging, Hôpital Necker Enfants-Malades, Paris, France
| | - M Leruez-Ville
- EA7328, Université de Paris & Institut IMAGINE, Paris, France
- Microbiology Department, Virology Unit, National Reference Centre for Herpes Virus and Congenital CMV Infection, Paris, France
| |
Collapse
|
30
|
Chavarot N, Ouedrani A, Marion O, Leruez-Ville M, Vilain E, Baaziz M, Del Bello A, Burger C, Sberro-Soussan R, Martinez F, Chatenoud L, Abravanel F, Anglicheau D, Izopet J, Couat C, Zuber J, Legendre C, Lanternier F, Kamar N, Scemla A. Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. Transplantation 2021; 105:e94-e95. [PMID: 33831941 DOI: 10.1097/tp.0000000000003784] [Citation(s) in RCA: 98] [Impact Index Per Article: 32.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Nathalie Chavarot
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Amani Ouedrani
- Université de Paris, Paris, France
- Immunology Laboratory, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- CNRS UMR8253, INSERM UMR1151, Institut Necker-Enfants Malades, Paris, France
| | - Olivier Marion
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France
- Toulouse III Paul Sabatier University, Toulouse, France
- Department of Nephrology and Organs Transplantation, Toulouse Rangueil University Hospital, Toulouse, France
| | - Marianne Leruez-Ville
- Université de Paris, Paris, France
- Virology Laboratory, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Estelle Vilain
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Maroua Baaziz
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Arnaud Del Bello
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France
- Toulouse III Paul Sabatier University, Toulouse, France
- Department of Nephrology and Organs Transplantation, Toulouse Rangueil University Hospital, Toulouse, France
| | - Carole Burger
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Rebecca Sberro-Soussan
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Frank Martinez
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Lucienne Chatenoud
- Université de Paris, Paris, France
- Immunology Laboratory, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- CNRS UMR8253, INSERM UMR1151, Institut Necker-Enfants Malades, Paris, France
| | - Florence Abravanel
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France
- Toulouse III Paul Sabatier University, Toulouse, France
- Virology Laboratory, Toulouse Purpan University Hospital, Toulouse, France
| | - Dany Anglicheau
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Jacques Izopet
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France
- Toulouse III Paul Sabatier University, Toulouse, France
- Virology Laboratory, Toulouse Purpan University Hospital, Toulouse, France
| | - Chloé Couat
- Department of Nephrology and Organs Transplantation, Toulouse Rangueil University Hospital, Toulouse, France
| | - Julien Zuber
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Christophe Legendre
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| | - Fanny Lanternier
- Université de Paris, Paris, France
- Department of Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Nassim Kamar
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France
- Toulouse III Paul Sabatier University, Toulouse, France
- Department of Nephrology and Organs Transplantation, Toulouse Rangueil University Hospital, Toulouse, France
| | - Anne Scemla
- Department of Nephrology and Kidney Transplantation, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
| |
Collapse
|
31
|
Fourgeaud J, Jamet A, Perot P, Regnault B, Troadec É, Chretien D, Bigot T, Eloit M, Ferroni A, Leruez-Ville M. Recherche d’agents pathogènes : une année de métagénomique clinique au laboratoire de microbiologie. Infect Dis Now 2021. [DOI: 10.1016/j.idnow.2021.06.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Runyo F, Beaudoin MC, Hammadi B, Morgand M, Driessen M, Sellier Y, Salomon LJ, Leruez-Ville M, Bille E, Lortholary O, Charlier C. Procalcitonin use for the screening of bacterial infections in pregnant women in the emergency ward: A prospective study. J Infect 2021; 83:e4-e5. [PMID: 34271061 DOI: 10.1016/j.jinf.2021.07.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Accepted: 07/11/2021] [Indexed: 10/20/2022]
Affiliation(s)
- Florence Runyo
- Infectious Diseases Department, Paris Centre Hospital, Université de Paris, 149 RUE DE SEVRES, 75743 PARIS CEDEX 15, France
| | - Marie Claude Beaudoin
- Infectious Diseases Department, Paris Centre Hospital, Université de Paris, 149 RUE DE SEVRES, 75743 PARIS CEDEX 15, France
| | - Boualem Hammadi
- Infectious Diseases Department, Paris Centre Hospital, Université de Paris, 149 RUE DE SEVRES, 75743 PARIS CEDEX 15, France
| | - Marjolaine Morgand
- Infectious Diseases Department, Paris Centre Hospital, Université de Paris, 149 RUE DE SEVRES, 75743 PARIS CEDEX 15, France
| | - Marine Driessen
- Infectious Diseases Department, Paris Centre Hospital, Université de Paris, 149 RUE DE SEVRES, 75743 PARIS CEDEX 15, France
| | - Yann Sellier
- Infectious Diseases Department, Paris Centre Hospital, Université de Paris, 149 RUE DE SEVRES, 75743 PARIS CEDEX 15, France
| | - Laurent J Salomon
- Infectious Diseases Department, Paris Centre Hospital, Université de Paris, 149 RUE DE SEVRES, 75743 PARIS CEDEX 15, France
| | - Marianne Leruez-Ville
- Infectious Diseases Department, Paris Centre Hospital, Université de Paris, 149 RUE DE SEVRES, 75743 PARIS CEDEX 15, France
| | - Emmanuelle Bille
- Infectious Diseases Department, Paris Centre Hospital, Université de Paris, 149 RUE DE SEVRES, 75743 PARIS CEDEX 15, France
| | - Olivier Lortholary
- Infectious Diseases Department, Paris Centre Hospital, Université de Paris, 149 RUE DE SEVRES, 75743 PARIS CEDEX 15, France
| | - Caroline Charlier
- Infectious Diseases Department, Paris Centre Hospital, Université de Paris, 149 RUE DE SEVRES, 75743 PARIS CEDEX 15, France.
| |
Collapse
|
33
|
Béziat V, Rapaport F, Hu J, Titeux M, Bonnet des Claustres M, Bourgey M, Griffin H, Bandet É, Ma CS, Sherkat R, Rokni-Zadeh H, Louis DM, Changi-Ashtiani M, Delmonte OM, Fukushima T, Habib T, Guennoun A, Khan T, Bender N, Rahman M, About F, Yang R, Rao G, Rouzaud C, Li J, Shearer D, Balogh K, Al Ali F, Ata M, Dabiri S, Momenilandi M, Nammour J, Alyanakian MA, Leruez-Ville M, Guenat D, Materna M, Marcot L, Vladikine N, Soret C, Vahidnezhad H, Youssefian L, Saeidian AH, Uitto J, Catherinot É, Navabi SS, Zarhrate M, Woodley DT, Jeljeli M, Abraham T, Belkaya S, Lorenzo L, Rosain J, Bayat M, Lanternier F, Lortholary O, Zakavi F, Gros P, Orth G, Abel L, Prétet JL, Fraitag S, Jouanguy E, Davis MM, Tangye SG, Notarangelo LD, Marr N, Waterboer T, Langlais D, Doorbar J, Hovnanian A, Christensen N, Bossuyt X, Shahrooei M, Casanova JL. Humans with inherited T cell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy. Cell 2021; 184:3812-3828.e30. [PMID: 34214472 PMCID: PMC8329841 DOI: 10.1016/j.cell.2021.06.004] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2020] [Revised: 02/03/2021] [Accepted: 06/02/2021] [Indexed: 12/18/2022]
Abstract
We study a patient with the human papilloma virus (HPV)-2-driven "tree-man" phenotype and two relatives with unusually severe HPV4-driven warts. The giant horns form an HPV-2-driven multifocal benign epithelial tumor overexpressing viral oncogenes in the epidermis basal layer. The patients are unexpectedly homozygous for a private CD28 variant. They have no detectable CD28 on their T cells, with the exception of a small contingent of revertant memory CD4+ T cells. T cell development is barely affected, and T cells respond to CD3 and CD2, but not CD28, costimulation. Although the patients do not display HPV-2- and HPV-4-reactive CD4+ T cells in vitro, they make antibodies specific for both viruses in vivo. CD28-deficient mice are susceptible to cutaneous infections with the mouse papillomavirus MmuPV1. The control of HPV-2 and HPV-4 in keratinocytes is dependent on the T cell CD28 co-activation pathway. Surprisingly, human CD28-dependent T cell responses are largely redundant for protective immunity.
Collapse
Affiliation(s)
- Vivien Béziat
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France; The Rockefeller University, New York, NY 10065, USA.
| | | | - Jiafen Hu
- Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
| | - Matthias Titeux
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France
| | | | | | | | - Élise Bandet
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France
| | - Cindy S Ma
- Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; St. Vincent's Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia
| | - Roya Sherkat
- Isfahan University of Medical Sciences, AIRC, Isfahan 81746-73461, Iran
| | | | - David M Louis
- Stanford University Medical School, Stanford, CA 94305, USA
| | | | - Ottavia M Delmonte
- National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
| | - Toshiaki Fukushima
- Institute of Innovative Research, Tokyo Institute of Technology, Yokohama 226-8501, Japan
| | | | | | | | - Noemi Bender
- German Cancer Research Center, 69120 Heidelberg, Germany
| | | | - Frédégonde About
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France
| | - Rui Yang
- The Rockefeller University, New York, NY 10065, USA
| | - Geetha Rao
- Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; St. Vincent's Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia
| | - Claire Rouzaud
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France; Necker Hospital for Sick Children, AP-HP, 75015 Paris, France
| | - Jingwei Li
- Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
| | - Debra Shearer
- Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
| | - Karla Balogh
- Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
| | | | | | - Soroosh Dabiri
- Zahedan University of Medical Sciences, 054 Zahedan, Iran
| | | | - Justine Nammour
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France
| | | | | | - David Guenat
- Papillomavirus National Reference Center, Besançon Hospital, 25030 Besançon, France
| | - Marie Materna
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France
| | - Léa Marcot
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France
| | - Natasha Vladikine
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France
| | - Christine Soret
- Papillomavirus National Reference Center, Besançon Hospital, 25030 Besançon, France
| | | | | | | | - Jouni Uitto
- Thomas Jefferson University, Philadelphia, PA 19107, USA
| | | | | | - Mohammed Zarhrate
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France
| | - David T Woodley
- University of Southern California, Los Angeles, CA 90033, USA
| | | | - Thomas Abraham
- Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
| | | | - Lazaro Lorenzo
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France
| | - Jérémie Rosain
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France; Necker Hospital for Sick Children, AP-HP, 75015 Paris, France
| | - Mousa Bayat
- Zahedan University of Medical Sciences, 054 Zahedan, Iran
| | - Fanny Lanternier
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France; Necker Hospital for Sick Children, AP-HP, 75015 Paris, France
| | - Olivier Lortholary
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France; Necker Hospital for Sick Children, AP-HP, 75015 Paris, France
| | - Faramarz Zakavi
- Ahvaz Jundishapur University of Medical Sciences, 061 Ahvaz, Iran
| | - Philippe Gros
- McGill University, Montreal, QC H3A 0G1, Canada; McGill Research Centre on Complex Traits, Montreal, QC H3G 0B1, Canada
| | | | - Laurent Abel
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France; The Rockefeller University, New York, NY 10065, USA
| | - Jean-Luc Prétet
- Papillomavirus National Reference Center, Besançon Hospital, 25030 Besançon, France
| | - Sylvie Fraitag
- Necker Hospital for Sick Children, AP-HP, 75015 Paris, France
| | - Emmanuelle Jouanguy
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France; The Rockefeller University, New York, NY 10065, USA
| | - Mark M Davis
- HHMI, Stanford University Medical School, Stanford, CA 94305, USA
| | - Stuart G Tangye
- Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; St. Vincent's Clinical School, UNSW Sydney, Sydney, NSW 2052, Australia
| | - Luigi D Notarangelo
- National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
| | | | - Tim Waterboer
- German Cancer Research Center, 69120 Heidelberg, Germany
| | - David Langlais
- McGill University, Montreal, QC H3A 0G1, Canada; McGill Research Centre on Complex Traits, Montreal, QC H3G 0B1, Canada
| | | | - Alain Hovnanian
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France; Necker Hospital for Sick Children, AP-HP, 75015 Paris, France
| | - Neil Christensen
- Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
| | | | - Mohammad Shahrooei
- University of Leuven, 3000 Leuven, Belgium; Dr. Shahrooei Lab, Ahvaz, Iran
| | - Jean-Laurent Casanova
- University of Paris, Imagine Institute, INSERM U1163, 75015 Paris, France; The Rockefeller University, New York, NY 10065, USA; HHMI, New York, NY 10065, USA.
| |
Collapse
|
34
|
Chavarot N, Divard G, Scemla A, Amrouche L, Aubert O, Leruez-Ville M, Timsit MO, Tinel C, Zuber J, Legendre C, Anglicheau D, Sberro-Soussan R. Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept. Am J Transplant 2021; 21:2448-2458. [PMID: 33283406 DOI: 10.1111/ajt.16430] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 11/23/2020] [Accepted: 11/24/2020] [Indexed: 01/25/2023]
Abstract
Belatacept may increase cytomegalovirus (CMV) disease risk after conversion from CNI-based therapy. We analyzed CMV disease characteristics after belatacept conversion. Propensity score matching was used to compare CMV disease incidence in belatacept- and CNI-treated kidney transplant recipients (KTRs). CMV disease characteristics and risk factors under belatacept were analyzed. In total, 223 KTRs (median age [IQR] 59.2 years [45.4-68.5]) were converted to belatacept (median of 11.5 months [2.5-37.0] post-transplantation); 40/223 (17.9%) developed CMV disease. Independent risk factors included increased age (p = .0164), D+/R- CMV serostatus (p = .0220), and low eGFR at conversion (p = .0355). Among 181 belatacept-treated patients matched to 181 controls, 32/181 (17.7%) experienced CMV disease (vs. 5/181 controls [2.8%]). CMV disease cumulative incidences were 6.33 and 0.91/100 person-years (p-y) in belatacept and control groups, respectively. CMV disease risk was particularly high in elderly patients (converted >70 years) and those with eGFR <30 ml/min; cumulative incidences were 18.4 and 5.2/100 p-y, respectively. CMV diseases under belatacept were atypical, with late-onset disease (24/40 patients [60%]), high CMV seropositivity (27/40, 67%), increased severe and tissue-invasive disease rates (gastrointestinal involvement in 32/40 [80%]) and life-threatening diseases (4/40 [10%]). These findings should stimulate further research to secure the use of belatacept as a valuable rescue therapy in KTRs.
Collapse
Affiliation(s)
- Nathalie Chavarot
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Necker-Enfants Malades Institute, French National Institute of Health and Medical Research U1151, Paris, France.,Université de Paris, Paris, France
| | - Gillian Divard
- INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France
| | - Anne Scemla
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Necker-Enfants Malades Institute, French National Institute of Health and Medical Research U1151, Paris, France.,Université de Paris, Paris, France
| | - Lucile Amrouche
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Necker-Enfants Malades Institute, French National Institute of Health and Medical Research U1151, Paris, France.,Université de Paris, Paris, France
| | - Olivier Aubert
- INSERM, Paris Translational Research Centre for Organ Transplantation, Paris, France
| | - Marianne Leruez-Ville
- Département of Virology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Marc O Timsit
- Université de Paris, Paris, France.,Department of Urology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Claire Tinel
- Necker-Enfants Malades Institute, French National Institute of Health and Medical Research U1151, Paris, France
| | - Julien Zuber
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Necker-Enfants Malades Institute, French National Institute of Health and Medical Research U1151, Paris, France.,Université de Paris, Paris, France
| | - Christophe Legendre
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Université de Paris, Paris, France
| | - Dany Anglicheau
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.,Necker-Enfants Malades Institute, French National Institute of Health and Medical Research U1151, Paris, France.,Université de Paris, Paris, France
| | - Rebecca Sberro-Soussan
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| |
Collapse
|
35
|
Berteloot L, Berthaud R, Temmam S, Lozach C, Zanelli E, Blanc T, Heloury Y, Capito C, Chardot C, Sarnacki S, Garcelon N, Lacaille F, Charbit M, Pastural M, Rabant M, Boddaert N, Leruez-Ville M, Eloit M, Sermet-Gaudelus I, Dehoux L, Boyer O. Arterial abnormalities identified in kidneys transplanted into children during the COVID-19 pandemic. Am J Transplant 2021; 21:1937-1943. [PMID: 33346946 PMCID: PMC9906447 DOI: 10.1111/ajt.16464] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Revised: 12/14/2020] [Accepted: 12/16/2020] [Indexed: 01/25/2023]
Abstract
Graft artery stenosis can have a significant short- and long-term negative impact on renal graft function. From the beginning of the COVID-19 pandemic, we noticed an unusual number of graft arterial anomalies following kidney transplant (KTx) in children. Nine children received a KTx at our center between February and July 2020, eight boys and one girl, of median age of 10 years. Seven presented Doppler features suggesting arterial stenosis, with an unusual extensive pattern. For comparison, over the previous 5-year period, persistent spectral Doppler arterial anomalies (focal anastomotic stenoses) following KTx were seen in 5% of children at our center. We retrospectively evidenced severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in five of seven children with arterial stenosis. The remaining two patients had received a graft from a deceased adolescent donor with a positive serology at D0. These data led us to suspect immune postviral graft vasculitis, triggered by SARS-CoV-2. Because the diagnosis of COVID-19 is challenging in children, we recommend pretransplant monitoring of graft recipients and their parents by monthly RT-PCR and serology. We suggest balancing the risk of postviral graft vasculitis against the risk of prolonged dialysis when considering transplantation in a child during the pandemic.
Collapse
Affiliation(s)
- Laureline Berteloot
- Pediatric Radiology Department, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France,INSERM U1163, Institut Imagine, Paris, France,Correspondence Laureline Berteloot, Pediatric Radiology Department, Hôpital universitaire Necker Enfants Malades, 149 rue de Sèvres, 75015, Paris, France.
| | - Romain Berthaud
- Pediatric Nephrology Department, MARHEA reference center, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France,Université de Paris, Paris, France
| | - Sarah Temmam
- Institut Pasteur, Laboratory of Pathogen Discovery, Paris, France
| | - Cécile Lozach
- Pediatric Radiology Department, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France,Université de Paris, Paris, France
| | - Elisa Zanelli
- Pediatric Radiology Department, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France,Université de Paris, Paris, France
| | - Thomas Blanc
- Université de Paris, Paris, France,Pediatric Surgery and Urology Department, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France
| | - Yves Heloury
- Université de Paris, Paris, France,Pediatric Surgery and Urology Department, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France
| | - Carmen Capito
- Pediatric Surgery and Urology Department, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France
| | - Christophe Chardot
- Université de Paris, Paris, France,Pediatric Surgery and Urology Department, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France
| | - Sabine Sarnacki
- Université de Paris, Paris, France,Pediatric Surgery and Urology Department, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France
| | - Nicolas Garcelon
- Data Science Platform, Paris Descartes—Sorbonne Paris Cite University, Institut Imagine, France
| | - Florence Lacaille
- Department of Pediatric Gastroenterology-Hepatology-Nutrition, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France
| | - Marina Charbit
- Pediatric Nephrology Department, MARHEA reference center, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France
| | | | - Marion Rabant
- Université de Paris, Paris, France,Department of Pathology, APHP, Hôpital Universitaire Necker-Enfants malades, Paris, France,INSERM U1151, Paris, France
| | - Nathalie Boddaert
- Pediatric Radiology Department, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France,INSERM U1163, Institut Imagine, Paris, France,Université de Paris, Paris, France
| | - Marianne Leruez-Ville
- Université de Paris, Paris, France,Virology Laboratory, APH-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France
| | - Marc Eloit
- Institut Pasteur, Laboratory of Pathogen Discovery, Paris, France
| | - Isabelle Sermet-Gaudelus
- Université de Paris, Paris, France,EA 7328 University of Paris, Institut Imagine, Paris, France,INSERM U1151, Institut Necker Enfants malades, National Cystic Fibrosis Reference Center, Paris, France
| | - Laurène Dehoux
- Pediatric Nephrology Department, MARHEA reference center, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France
| | - Olivia Boyer
- INSERM U1163, Institut Imagine, Paris, France,Pediatric Nephrology Department, MARHEA reference center, AP-HP, Hôpital Universitaire Necker-Enfants malades, Paris, France,Université de Paris, Paris, France
| |
Collapse
|
36
|
Leruez-Ville M, Guilleminot T, Stirnemann J, Salomon LJ, Spaggiari E, Faure-Bardon V, Magny JF, Ville Y. Quantifying the Burden of Congenital Cytomegalovirus Infection With Long-term Sequelae in Subsequent Pregnancies of Women Seronegative at Their First Pregnancy. Clin Infect Dis 2021; 71:1598-1603. [PMID: 31665306 DOI: 10.1093/cid/ciz1067] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Accepted: 10/25/2019] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND In women seronegative before pregnancy, congenital cytomegalovirus (cCMV)-related sequelae are exclusively seen in those infected in the first trimester of pregnancy. Following a maternal primary infection in the first trimester, up to 30% of infected neonates suffer long-term sequelae. Maternal parity is an established risk factor of cCMV in previously seronegative women. Our objective was to quantify, in a population of women seronegative at their first pregnancy, the risk of cCMV and related sequelae following primary infections in the first trimester in subsequent pregnancies. METHODS There were 739 women seronegative at their first pregnancy who had at least 1 of 971 subsequent pregnancies and deliveries managed at our institution. All women had CMV immunoglobin (Ig) G and IgM testing at 11-14 weeks of each pregnancy. RESULTS Between 2 consecutive pregnancies, 15.6% (115/739) of women seroconverted. Of these seroconversions, 29% (33/115) occurred in the periconceptional period or in the first trimester. The risks for cCMV and related sequelae (neurologic and/or hearing loss) following a maternal infection in the first trimester were, respectively, 24- and 6-fold higher (risk ratios, 24 [95% confidence interval {CI}, 10.8-62.3] and 6 [95% CI 1.5-24], respectively) than in the general pregnant population. Of all primary maternal infections and fetal infections in the first trimester, 88% (29/33) and 92% (11/12), respectively, occurred when the inter-pregnancy interval was ≤2 years. CONCLUSIONS Women seronegative at their first pregnancy with a subsequent pregnancy within 2 years have the highest risk of delivering a child with cCMV-related sequelae. These women should be made aware of the risk and given the opportunity of serology screening in the first trimester.
Collapse
Affiliation(s)
- Marianne Leruez-Ville
- Paris Descartes University, Paris, France.,Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections, Assistance Publique-Hopitaux de Paris, Hospital Necker, Paris, France
| | - Tiffany Guilleminot
- Paris Descartes University, Paris, France.,Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections, Assistance Publique-Hopitaux de Paris, Hospital Necker, Paris, France
| | - Julien Stirnemann
- Paris Descartes University, Paris, France.,Maternity, Assistance Publique-Hopitaux de Paris, Hospital Necker, Paris, France
| | - Laurent J Salomon
- Paris Descartes University, Paris, France.,Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections, Assistance Publique-Hopitaux de Paris, Hospital Necker, Paris, France
| | - Emmanuel Spaggiari
- Paris Descartes University, Paris, France.,Maternity, Assistance Publique-Hopitaux de Paris, Hospital Necker, Paris, France
| | - Valentine Faure-Bardon
- Paris Descartes University, Paris, France.,Maternity, Assistance Publique-Hopitaux de Paris, Hospital Necker, Paris, France
| | - Jean-Francois Magny
- Paris Descartes University, Paris, France.,Neonatal Intensive Care Unit, Assistance Publique-Hopitaux de Paris, Hospital Necker, Paris, France
| | - Yves Ville
- Paris Descartes University, Paris, France.,Maternity, Assistance Publique-Hopitaux de Paris, Hospital Necker, Paris, France
| |
Collapse
|
37
|
Faure-Bardon V, Fourgeaud J, Guilleminot T, Magny JF, Salomon LJ, Bernard JP, Leruez-Ville M, Ville Y. First-trimester diagnosis of congenital cytomegalovirus infection after maternal primary infection in early pregnancy: feasibility study of viral genome amplification by PCR on chorionic villi obtained by CVS. Ultrasound Obstet Gynecol 2021; 57:568-572. [PMID: 33533526 DOI: 10.1002/uog.23608] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 01/22/2021] [Accepted: 01/25/2021] [Indexed: 06/12/2023]
Abstract
OBJECTIVE To evaluate the feasibility of amplification of the viral genome by polymerase chain reaction (PCR) analysis of trophoblast samples obtained by chorionic villus sampling (CVS) in cases of maternal primary infection (MPI) with cytomegalovirus (CMV) in early pregnancy. METHODS This was a prospective study carried out at the Department of Obstetrics and Fetal Medicine, Hopital Necker-E.M., between October 2019 and October 2020. Following CMV serology screening in early pregnancy, CVS was offered to women at 11-14 weeks' gestation after CMV-MPI ≤ 10 weeks. Array-comparative genomic hybridization and amplification of the viral genome by PCR were performed on the trophoblasts obtained by CVS. All cases also underwent amniocentesis from 17 weeks onwards and PCR was performed on the amniotic fluid. Secondary prevention with valacyclovir was initiated as soon as MPI was diagnosed, to decrease the risk of vertical transmission. We evaluated the diagnostic performance of CMV-PCR of trophoblast obtained by CVS, using as the reference standard PCR of amniotic fluid obtained by amniocentesis. RESULTS CVS was performed in 37 pregnancies, at a median (range) gestational age of 12.7 (11.3-14.4) weeks. CMV-PCR in chorionic villi was positive in three and negative in 34 cases. CMV-PCR following amniocentesis, performed at a median (range) gestational age of 17.6 (16.7-29.9) weeks, was positive for the three cases which were positive following CVS and, of the 34 patients with a negative finding following CVS, amniocentesis was negative in 31 and positive in three. The sensitivity of CMV-PCR analysis of trophoblast obtained by CVS for the diagnosis of CMV, using as the reference standard PCR analysis of amniotic fluid obtained by amniocentesis, was 50% (95% CI, 19-81%), specificity was 100% (95% CI, 89-100%), positive predictive value was 100% (95% CI, 44-100%) and negative predictive value was 91% (95% CI, 77-97%). CONCLUSIONS Diagnosis of placental infection following MPI in early pregnancy can be achieved by PCR amplification of the CMV genome in chorionic villi. We propose that negative CMV-PCR in the trophoblast after 12 weeks could be used to exclude CMV-related embryopathy leading to sequelae. However, this needs to be confirmed through long-term follow-up evaluation. These findings could help to establish CVS as the diagnostic test of choice following maternal serology screening in early pregnancy. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
Collapse
Affiliation(s)
- V Faure-Bardon
- EA 73-28, Université de Paris, Paris, France
- AP-HP, Department of Obstetrics and Fetal Medicine, Hopital Necker-E.M., Paris, France
| | - J Fourgeaud
- EA 73-28, Université de Paris, Paris, France
- AP-HP, Virology Laboratory, Hopital Necker-E.M., Paris, France
| | - T Guilleminot
- EA 73-28, Université de Paris, Paris, France
- AP-HP, Virology Laboratory, Hopital Necker-E.M., Paris, France
| | - J-F Magny
- EA 73-28, Université de Paris, Paris, France
- AP-HP, Neonatal Intensive Care Unit, Hopital Necker-E.M, Paris, France
| | - L J Salomon
- EA 73-28, Université de Paris, Paris, France
- AP-HP, Department of Obstetrics and Fetal Medicine, Hopital Necker-E.M., Paris, France
| | - J-P Bernard
- EA 73-28, Université de Paris, Paris, France
- AP-HP, Department of Obstetrics and Fetal Medicine, Hopital Necker-E.M., Paris, France
| | - M Leruez-Ville
- EA 73-28, Université de Paris, Paris, France
- AP-HP, Virology Laboratory, Hopital Necker-E.M., Paris, France
| | - Y Ville
- EA 73-28, Université de Paris, Paris, France
- AP-HP, Department of Obstetrics and Fetal Medicine, Hopital Necker-E.M., Paris, France
| |
Collapse
|
38
|
Sermet-Gaudelus I, Temmam S, Huon C, Behillil S, Gajdos V, Bigot T, Lurier T, Chrétien D, Backovic M, Delaunay-Moisan A, Donati F, Albert M, Foucaud E, Mesplées B, Benoist G, Faye A, Duval-Arnould M, Cretolle C, Charbit M, Aubart M, Auriau J, Lorrot M, Kariyawasam D, Fertitta L, Orliaguet G, Pigneur B, Bader-Meunier B, Briand C, Enouf V, Toubiana J, Guilleminot T, van der Werf S, Leruez-Ville M, Eloit M. Prior infection by seasonal coronaviruses, as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, France, April to June 2020. Euro Surveill 2021; 26:2001782. [PMID: 33797390 PMCID: PMC8017906 DOI: 10.2807/1560-7917.es.2021.26.13.2001782] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Accepted: 03/07/2021] [Indexed: 01/10/2023] Open
Abstract
BackgroundChildren have a low rate of COVID-19 and secondary severe multisystem inflammatory syndrome (MIS) but present a high prevalence of symptomatic seasonal coronavirus infections.AimWe tested if prior infections by seasonal coronaviruses (HCoV) NL63, HKU1, 229E or OC43 as assessed by serology, provide cross-protective immunity against SARS-CoV-2 infection.MethodsWe set a cross-sectional observational multicentric study in pauci- or asymptomatic children hospitalised in Paris during the first wave for reasons other than COVID (hospitalised children (HOS), n = 739) plus children presenting with MIS (n = 36). SARS-CoV-2 antibodies directed against the nucleoprotein (N) and S1 and S2 domains of the spike (S) proteins were monitored by an in-house luciferase immunoprecipitation system assay. We randomly selected 69 SARS-CoV-2-seropositive patients (including 15 with MIS) and 115 matched SARS-CoV-2-seronegative patients (controls (CTL)). We measured antibodies against SARS-CoV-2 and HCoV as evidence for prior corresponding infections and assessed if SARS-CoV-2 prevalence of infection and levels of antibody responses were shaped by prior seasonal coronavirus infections.ResultsPrevalence of HCoV infections were similar in HOS, MIS and CTL groups. Antibody levels against HCoV were not significantly different in the three groups and were not related to the level of SARS-CoV-2 antibodies in the HOS and MIS groups. SARS-CoV-2 antibody profiles were different between HOS and MIS children.ConclusionPrior infection by seasonal coronaviruses, as assessed by serology, does not interfere with SARS-CoV-2 infection and related MIS in children.
Collapse
Affiliation(s)
- Isabelle Sermet-Gaudelus
- Institut Necker Enfants Malades, INSERM U 1171, Paris, France
- Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
- Université de Paris, Paris, France
- These authors contributed equally to the work
| | - Sarah Temmam
- These authors contributed equally to the work
- Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France
| | - Christèle Huon
- Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France
| | - Sylvie Behillil
- Molecular Genetics of RNA Viruses, Department of Virology, CNRS UMR3569, Université de Paris, Institut Pasteur, Paris, France
- National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France
| | - Vincent Gajdos
- Hôpital Antoine Beclere, Clamart, France
- Centre for Research in Epidemiology and Population Health, INSERM UMR1018, Villejuif, France
| | - Thomas Bigot
- Hub de Bioinformatique et Biostatistique - Département Biologie Computationnelle, Institut Pasteur, USR 3756 CNRS, Paris, France
- Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France
| | - Thibaut Lurier
- Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, Saint-Genès-Champanelle, France
- Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, Marcy l'Etoile, France
- Université de Lyon, INRAE, VetAgro Sup, Usc 1233 UR RS2GP, Marcy l'Etoile, France
| | - Delphine Chrétien
- Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France
| | - Marija Backovic
- Unité de Virologie Structurale, Institut Pasteur, Département de Virologie, CNRS, UMR3569, Paris, France
| | - Agnès Delaunay-Moisan
- Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette, France
| | - Flora Donati
- Molecular Genetics of RNA Viruses, Department of Virology, CNRS UMR3569, Université de Paris, Institut Pasteur, Paris, France
- National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France
| | - Mélanie Albert
- Molecular Genetics of RNA Viruses, Department of Virology, CNRS UMR3569, Université de Paris, Institut Pasteur, Paris, France
- National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France
| | | | | | | | | | | | - Célia Cretolle
- Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Marina Charbit
- Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Mélodie Aubart
- Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Johanne Auriau
- Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
| | | | | | - Laura Fertitta
- Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Gilles Orliaguet
- Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Bénédicte Pigneur
- Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
| | | | | | - Vincent Enouf
- Plateforme de microbiologie mutualisée (P2M), Pasteur International Bioresources Network (PIBnet), Institut Pasteur, Paris, France
- Molecular Genetics of RNA Viruses, Department of Virology, CNRS UMR3569, Université de Paris, Institut Pasteur, Paris, France
- National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France
| | - Julie Toubiana
- Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France
- Unité Biodiversité et Epidemiologie des Bacteries Pathogènes, Institut Pasteur, Paris, France
- Université de Paris, Paris, France
| | | | - Sylvie van der Werf
- Molecular Genetics of RNA Viruses, Department of Virology, CNRS UMR3569, Université de Paris, Institut Pasteur, Paris, France
- National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France
| | | | - Marc Eloit
- Ecole Nationale Vétérinaire d'Alfort, Maisons Alfort, France
- Pathogen Discovery Laboratory, Department of Virology, Institut Pasteur, Paris, France
| |
Collapse
|
39
|
Vauloup-Fellous C, Maylin S, Périllaud-Dubois C, Brichler S, Alloui C, Gordien E, Rameix-Welti MA, Gault E, Moreau F, Fourati S, Challine D, Pawlotsky JM, Houhou-Fidouh N, Damond F, Mackiewicz V, Charpentier C, Méritet JF, Rozenberg F, Podglajen I, Marot S, Petit H, Burrel S, Akhavan S, Leruez-Ville M, Avettand-Fenoel V, Fourgeaud J, Guilleminot T, Gardiennet E, Bonacorsi S, Carol A, Carcelain G, Villemonteix J, Boukli N, Gozlan J, Morand-Joubert L, Legoff J, Delaugerre C, Chaix ML, Roque-Afonso AM, Dortet L, Naas T, Ronat JB, Lepape S, Marcelin AG, Descamps D. Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients. Eur J Clin Microbiol Infect Dis 2021; 40:2235-2241. [PMID: 33782783 PMCID: PMC8007057 DOI: 10.1007/s10096-021-04232-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2021] [Accepted: 03/17/2021] [Indexed: 01/08/2023]
Abstract
We report evaluation of 30 assays' (17 rapid tests (RDTs) and 13 automated/manual ELISA/CLIA assay (IAs)) clinical performances with 2594 sera collected from symptomatic patients with positive SARS-CoV-2 rRT-PCR on a respiratory sample, and 1996 pre-epidemic serum samples expected to be negative. Only 4 RDT and 3 IAs fitted both specificity (> 98%) and sensitivity (> 90%) criteria according to French recommendations. Serology may offer valuable information during COVID-19 pandemic, but inconsistent performances observed among the 30 commercial assays evaluated, which underlines the importance of independent evaluation before clinical implementation.
Collapse
Affiliation(s)
- Christelle Vauloup-Fellous
- AP-HP, Hôpital Paul-Brousse, Virologie, Department of Virology, University Paris Saclay, INSERM U1193, 94804, Villejuif, France.
| | - Sarah Maylin
- Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Université de Paris, INSERM UMR 944, Paris, France
| | - Claire Périllaud-Dubois
- AP-HP, Hôpital Paul-Brousse, Virologie, Department of Virology, University Paris Saclay, INSERM U1193, 94804, Villejuif, France
| | - Ségolène Brichler
- Laboratoire de Microbiologie Clinique, Centre national de référence des hépatites B, C et Delta, Hôpital Avicenne, Université Paris Nord, 93009, Bobigny, France.,Unité INSERM U955, Créteil, France
| | - Chakib Alloui
- Laboratoire de Microbiologie Clinique, Centre national de référence des hépatites B, C et Delta, Hôpital Avicenne, Université Paris Nord, 93009, Bobigny, France.,Unité INSERM U955, Créteil, France
| | - Emmanuel Gordien
- Laboratoire de Microbiologie Clinique, Centre national de référence des hépatites B, C et Delta, Hôpital Avicenne, Université Paris Nord, 93009, Bobigny, France.,Unité INSERM U955, Créteil, France
| | - Marie-Anne Rameix-Welti
- Laboratoire de Microbiologie, AP-HP. Université Paris Saclay, Hôpital Ambroise Paré, Boulogne-Billancourt, France.,INSERM, Université Paris-Saclay, Université de Versailles St. Quentin, UMR 1173 (2I), Versailles, France
| | - Elyanne Gault
- Laboratoire de Microbiologie, AP-HP. Université Paris Saclay, Hôpital Ambroise Paré, Boulogne-Billancourt, France.,INSERM, Université Paris-Saclay, Université de Versailles St. Quentin, UMR 1173 (2I), Versailles, France
| | - Frédérique Moreau
- Laboratoire de Microbiologie, AP-HP. Université Paris Saclay, Hôpital Ambroise Paré, Boulogne-Billancourt, France.,INSERM, Université Paris-Saclay, Université de Versailles St. Quentin, UMR 1173 (2I), Versailles, France
| | - Slim Fourati
- Department of Virology, Hôpital Henri Mondor, "Viruses, Hepatology, Cancer" Research Unit, Université Paris-Est, INSERM U955, Créteil, France
| | - Dominique Challine
- Department of Virology, Hôpital Henri Mondor, "Viruses, Hepatology, Cancer" Research Unit, Université Paris-Est, INSERM U955, Créteil, France
| | - Jean-Michel Pawlotsky
- Department of Virology, Hôpital Henri Mondor, "Viruses, Hepatology, Cancer" Research Unit, Université Paris-Est, INSERM U955, Créteil, France
| | - Nadhira Houhou-Fidouh
- Laboratoire de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université de Paris, INSERM UMR 1137 IAME, F-75018, Paris, France
| | - Florence Damond
- Laboratoire de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université de Paris, INSERM UMR 1137 IAME, F-75018, Paris, France
| | - Vincent Mackiewicz
- Laboratoire de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université de Paris, INSERM UMR 1137 IAME, F-75018, Paris, France
| | - Charlotte Charpentier
- Laboratoire de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université de Paris, INSERM UMR 1137 IAME, F-75018, Paris, France
| | - Jean-François Méritet
- Service de Virologie, Hôpital Cochin - APHP Centre - Université de Paris, Paris, France
| | - Flore Rozenberg
- Service de Virologie, Hôpital Cochin - APHP Centre - Université de Paris, Paris, France
| | - Isabelle Podglajen
- Service de Virologie, Hôpital Européen Georges Pompidou-APHP Centre - Université de Paris, Paris, France
| | - Stéphane Marot
- Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Sorbonne Université, INSERM, Paris, France
| | - Heloïse Petit
- Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Sorbonne Université, INSERM, Paris, France
| | - Sonia Burrel
- Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Sorbonne Université, INSERM, Paris, France
| | - Sepideh Akhavan
- Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Sorbonne Université, INSERM, Paris, France
| | - Marianne Leruez-Ville
- APHP Laboratoire de Microbiologie clinique, Hôpital Necker, Université de Paris, Faculté de Médecine, INSERM U1016, CNRS UMR 8104, Institut Cochin, Paris, France
| | - Véronique Avettand-Fenoel
- APHP Laboratoire de Microbiologie clinique, Hôpital Necker, Université de Paris, Faculté de Médecine, INSERM U1016, CNRS UMR 8104, Institut Cochin, Paris, France
| | - Jacques Fourgeaud
- APHP Laboratoire de Microbiologie clinique, Hôpital Necker, Université de Paris, Faculté de Médecine, INSERM U1016, CNRS UMR 8104, Institut Cochin, Paris, France
| | - Tiffany Guilleminot
- APHP Laboratoire de Microbiologie clinique, Hôpital Necker, Université de Paris, Faculté de Médecine, INSERM U1016, CNRS UMR 8104, Institut Cochin, Paris, France
| | - Elise Gardiennet
- APHP Laboratoire de Microbiologie clinique, Hôpital Necker, Université de Paris, Faculté de Médecine, INSERM U1016, CNRS UMR 8104, Institut Cochin, Paris, France
| | - Stéphane Bonacorsi
- Service de Microbiologie, Hôpital Robert-Debré, Université de Paris, Paris, France
| | - Agnès Carol
- Service de Microbiologie, Hôpital Robert-Debré, Université de Paris, Paris, France
| | - Guislaine Carcelain
- Laboratoire d'immunologie, Hôpital Robert-Debré, Université de Paris, Paris, France
| | | | - Narjis Boukli
- Département de Virologie (Hôpital Saint-Antoine, Tenon, Trousseau), AP-HP Sorbonne Université, INSERM-Sorbonne Universités UPMC, Université Paris 06, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France
| | - Joël Gozlan
- Département de Virologie (Hôpital Saint-Antoine, Tenon, Trousseau), AP-HP Sorbonne Université, INSERM-Sorbonne Universités UPMC, Université Paris 06, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France
| | - Laurence Morand-Joubert
- Département de Virologie (Hôpital Saint-Antoine, Tenon, Trousseau), AP-HP Sorbonne Université, INSERM-Sorbonne Universités UPMC, Université Paris 06, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France
| | - Jérome Legoff
- Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Université de Paris, INSERM UMR 944, Paris, France
| | - Constance Delaugerre
- Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Université de Paris, INSERM UMR 944, Paris, France
| | - Marie-Laure Chaix
- Département des Agents Infectieux, Service de Virologie, Hôpital Saint-Louis, Université de Paris, INSERM UMR 944, Paris, France
| | - Ana-Maria Roque-Afonso
- AP-HP, Hôpital Paul-Brousse, Virologie, Department of Virology, University Paris Saclay, INSERM U1193, 94804, Villejuif, France
| | - Laurent Dortet
- Service de Bactériologie-Hygiène, Hôpital Bicêtre, Inserm U 1184; LabEx LERMIT, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Thierry Naas
- Service de Bactériologie-Hygiène, Hôpital Bicêtre, Inserm U 1184; LabEx LERMIT, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Jean-Baptiste Ronat
- Service de Bactériologie-Hygiène, Hôpital Bicêtre, Inserm U 1184; LabEx LERMIT, Université Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Samuel Lepape
- AP-HP, Hôpital Paul-Brousse, Virologie, Department of Virology, University Paris Saclay, INSERM U1193, 94804, Villejuif, France
| | - Anne-Geneviève Marcelin
- Institut Pierre Louis d'Epidémiologie et de Santé Publique, IPLESP, AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Sorbonne Université, INSERM, Paris, France
| | - Diane Descamps
- Laboratoire de Virologie, AP-HP, Hôpital Bichat-Claude Bernard, Université de Paris, INSERM UMR 1137 IAME, F-75018, Paris, France
| |
Collapse
|
40
|
Rolland M, Martin H, Bergamelli M, Sellier Y, Bessières B, Aziza J, Benchoua A, Leruez-Ville M, Gonzalez-Dunia D, Chavanas S. Human cytomegalovirus infection is associated with increased expression of the lissencephaly gene PAFAH1B1 encoding LIS1 in neural stem cells and congenitally infected brains. J Pathol 2021; 254:92-102. [PMID: 33565082 DOI: 10.1002/path.5640] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Revised: 02/02/2021] [Accepted: 02/05/2021] [Indexed: 12/22/2022]
Abstract
Congenital infection of the central nervous system by human cytomegalovirus (HCMV) is a leading cause of permanent sequelae, including mental retardation or neurodevelopmental abnormalities. The most severe complications include smooth brain or polymicrogyria, which are both indicative of abnormal migration of neural cells, although the underlying mechanisms remain to be determined. To gain better insight on the pathogenesis of such sequelae, we assessed the expression levels of a set of neurogenesis-related genes, using HCMV-infected human neural stem cells derived from embryonic stem cells (NSCs). Among the 84 genes tested, we found dramatically increased expression of the gene PAFAH1B1, encoding LIS1 (lissencephaly-1), in HCMV-infected versus uninfected NSCs. Consistent with these findings, western blotting and immunofluorescence analyses confirmed the increased levels of LIS1 in HCMV-infected NSCs at the protein level. We next assessed the migratory abilities of HCMV-infected NSCs and observed that infection strongly impaired the migration of NSCs, without detectable effect on their proliferation. Moreover, we observed increased immunostaining for LIS1 in brains of congenitally infected fetuses, but not in control samples, highlighting the clinical relevance of our findings. Of note, PAFAH1B1 mutations (resulting in either haploinsufficiency or gain of function) are primary causes of hereditary neurodevelopmental diseases. Notably, mutations resulting in PAFAH1B1 haploinsufficiency cause classic lissencephaly. Taken together, our findings suggest that PAFAH1B1 is a critical target of HCMV infection. They also shine a new light on the pathophysiological basis of the neurological outcomes of congenital HCMV infection, by suggesting that defective neural cell migration might contribute to the pathogenesis of the neurodevelopmental sequelae of infection. © 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Maude Rolland
- Centre for Pathophysiology Toulouse-Purpan (CPTP), INSERM, CNRS, University of Toulouse, Toulouse, France
| | - Hélène Martin
- Centre for Pathophysiology Toulouse-Purpan (CPTP), INSERM, CNRS, University of Toulouse, Toulouse, France
| | - Mathilde Bergamelli
- Centre for Pathophysiology Toulouse-Purpan (CPTP), INSERM, CNRS, University of Toulouse, Toulouse, France
| | - Yann Sellier
- Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.,Université Paris Descartes, Paris, France
| | - Bettina Bessières
- Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.,Université Paris Descartes, Paris, France
| | - Jacqueline Aziza
- Département d'Anatomie Pathologique, IUCT-Oncopôle Toulouse, Toulouse, France
| | | | - Marianne Leruez-Ville
- Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France.,Université Paris Descartes, Paris, France
| | - Daniel Gonzalez-Dunia
- Centre for Pathophysiology Toulouse-Purpan (CPTP), INSERM, CNRS, University of Toulouse, Toulouse, France
| | - Stéphane Chavanas
- Centre for Pathophysiology Toulouse-Purpan (CPTP), INSERM, CNRS, University of Toulouse, Toulouse, France
| |
Collapse
|
41
|
Contejean A, Leporrier J, Canouï E, Fourgeaud J, Mariaggi AA, Alby-Laurent F, Lafont E, Beaudeau L, Rouzaud C, Lecieux F, Greffet A, L'Honneur AS, Tréluyer JM, Lanternier F, Casetta A, Frange P, Leruez-Ville M, Rozenberg F, Lortholary O, Kernéis S. Transmission Routes of Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers of a French University Hospital in Paris, France. Open Forum Infect Dis 2021; 8:ofab054. [PMID: 33723511 PMCID: PMC7928692 DOI: 10.1093/ofid/ofab054] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Accepted: 01/28/2021] [Indexed: 11/14/2022] Open
Abstract
In this case-control study on 564 healthcare workers of a university hospital in Paris (France), contacts without protection with coronavirus disease 2019 (COVID-19) patients or with colleagues were associated with infection with severe acute respiratory syndrome coronavirus 2, whereas working in a COVID-dedicated unit and having children kept in childcare facilities were not.
Collapse
Affiliation(s)
- Adrien Contejean
- Université de Paris, Faculté de Médecine, Paris, France.,Equipe Mobile d'Infectiologie, AP-HP, Hôpital Cochin, Paris, France
| | - Jérémie Leporrier
- Service de maladies Infectieuses et Tropicales, AP-HP, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France
| | - Etienne Canouï
- Equipe Mobile d'Infectiologie, AP-HP, Hôpital Cochin, Paris, France
| | - Jacques Fourgeaud
- Laboratoire de Virologie, AP-HP, Hôpital Necker-Enfants malades, Paris, France.,EHU 7328 PACT, Institut Imagine, Université de Paris, Faculté de Médecine, Paris, France
| | | | - Fanny Alby-Laurent
- Université de Paris, Faculté de Médecine, Paris, France.,Service de maladies Infectieuses et Tropicales, AP-HP, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France
| | - Emmanuel Lafont
- Université de Paris, Faculté de Médecine, Paris, France.,Service de maladies Infectieuses et Tropicales, AP-HP, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France
| | - Lauren Beaudeau
- Equipe Mobile d'Infectiologie, AP-HP, Hôpital Cochin, Paris, France
| | - Claire Rouzaud
- Service de maladies Infectieuses et Tropicales, AP-HP, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France
| | - Fabienne Lecieux
- Service de Santé au Travail, AP-HP, Hôpital Cochin, Paris, France
| | - Agnès Greffet
- Service de Santé au Travail, AP-HP, Hôpital Necker-Enfants malades, Paris, France
| | | | - Jean-Marc Tréluyer
- Département de Soins Intensifs Pédiatriques, AP-HP, Hôpital Necker-Enfants malades, Paris, France.,Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Université de Paris, Faculté de Médecine, Paris, France.,Département de Pharmacologie Clinique AP-HP, Hôpital Cochin, Paris, France
| | - Fanny Lanternier
- Université de Paris, Faculté de Médecine, Paris, France.,Service de maladies Infectieuses et Tropicales, AP-HP, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France
| | - Anne Casetta
- Equipe opérationnelle d'hygiène Hospitalière, AP-HP, Hôpital Cochin, Paris, France
| | - Pierre Frange
- EHU 7328 PACT, Institut Imagine, Université de Paris, Faculté de Médecine, Paris, France.,Laboratoire de Microbiologie Clinique, AP-HP, Hôpital Necker-Enfants malades, Paris, France
| | - Marianne Leruez-Ville
- Laboratoire de Virologie, AP-HP, Hôpital Necker-Enfants malades, Paris, France.,EHU 7328 PACT, Institut Imagine, Université de Paris, Faculté de Médecine, Paris, France
| | - Flore Rozenberg
- Département de Virologie, AP-HP, Hôpital Cochin, Paris, France.,Université de Paris, Institut Cochin, INSERM U1016, CNRS UMR8104, Paris, France
| | - Olivier Lortholary
- Université de Paris, Faculté de Médecine, Paris, France.,Service de maladies Infectieuses et Tropicales, AP-HP, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France.,Institut Pasteur, Molecular Mycology Unit, National Reference Centre for Invasive Mycoses and Antifungals, CNRS UMR 2000, Paris, France
| | - Solen Kernéis
- Equipe Mobile d'Infectiologie, AP-HP, Hôpital Cochin, Paris, France.,Université de Paris, INSERM, IAME, Paris, France.,Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France
| |
Collapse
|
42
|
Chavarot N, Leruez-Ville M, Scemla A, Burger C, Amrouche L, Rouzaud C, Lebreton X, Martinez F, Sberro-Soussan R, Legendre C, Zuber J, Anglicheau D. Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection. Kidney Int 2021; 99:486-488. [PMID: 33509358 PMCID: PMC7830266 DOI: 10.1016/j.kint.2020.12.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Accepted: 12/07/2020] [Indexed: 02/07/2023]
Affiliation(s)
- Nathalie Chavarot
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
| | - Marianne Leruez-Ville
- Université de Paris, Paris, France; Department of Virology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Anne Scemla
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Carole Burger
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Lucile Amrouche
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Claire Rouzaud
- Université de Paris, Paris, France; Department of Infectious Diseases and Tropical Medicine, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Xavier Lebreton
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Frank Martinez
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Rebecca Sberro-Soussan
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Christophe Legendre
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Julien Zuber
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Dany Anglicheau
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| |
Collapse
|
43
|
Faure-Bardon V, Isnard P, Roux N, Leruez-Ville M, Molina T, Bessieres B, Ville Y. Reply. Ultrasound Obstet Gynecol 2021; 57:352-353. [PMID: 33524233 DOI: 10.1002/uog.23583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Affiliation(s)
- V Faure-Bardon
- EA 73-28, Université de Paris, Paris, France
- AP-HP, Department of Obstetrics and Fetal Medicine, Hospital Necker-E.M., Paris, France
| | - P Isnard
- AP-HP, Department of Histology, Embryology and Cytogenetics, Hospital Necker-E.M, Paris, France
- Institut National de la Santé et de la Recherche Médicale (INSERM), U1151, CNRS UMR 8253, Hospital Necker-E.M., Department of Growth and Signaling, Université de Paris, Paris, France
| | - N Roux
- AP-HP, Department of Histology, Embryology and Cytogenetics, Hospital Necker-E.M, Paris, France
| | - M Leruez-Ville
- EA 73-28, Université de Paris, Paris, France
- AP-HP, Virology Laboratory, Hospital Necker-E.M, Paris, France
| | - T Molina
- AP-HP, Department of Histology, Embryology and Cytogenetics, Hospital Necker-E.M, Paris, France
| | - B Bessieres
- AP-HP, Department of Histology, Embryology and Cytogenetics, Hospital Necker-E.M, Paris, France
| | - Y Ville
- EA 73-28, Université de Paris, Paris, France
- AP-HP, Department of Obstetrics and Fetal Medicine, Hospital Necker-E.M., Paris, France
| |
Collapse
|
44
|
Contejean A, Leporrier J, Canouï E, Alby-Laurent F, Lafont E, Beaudeau L, Parize P, Lecieux F, Greffet A, Chéron G, Gauzit R, Fourgeaud J, L'Honneur AS, Tréluyer JM, Charlier C, Casetta A, Frange P, Leruez-Ville M, Rozenberg F, Lortholary O, Kernéis S. Comparing Dynamics and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 Transmissions Among Healthcare Workers of Adult and Pediatric Settings in Central Paris. Clin Infect Dis 2021; 72:257-264. [PMID: 33501952 PMCID: PMC7454459 DOI: 10.1093/cid/ciaa977] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Accepted: 07/09/2020] [Indexed: 01/10/2023] Open
Abstract
Background Health-care workers (HCW) have paid a heavy toll to the coronavirus disease-19 (COVID-19) outbreak. Routes of transmission remain to be fully understood. Methods This prospective study compared a 1,500-bed adult and a 600-bed pediatric setting of a tertiary-care university hospital located in central Paris. From February 24th until April 10th, 2020, all symptomatic HCW were screened for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) on a nasopharyngeal swab. HCW screened positive were questioned on their profession, symptoms, occupational and non-occupational exposures to SARS-CoV-2. Results Among 1344 HCW tested, 373 were positive (28%) and 336 (90%) corresponding questionnaires were completed. Three hospitalizations and no death were reported. Most HCW (70%) had patient-facing occupational activities (22% in COVID-19 dedicated units). The total number of HCW cases peaked on March 23rd, then decreased slowly, concomitantly with a continuous increase of compliance to preventive measures (including universal medical masking and personal protective equipment (PPE) for direct care to COVID-19 patients). Attack rates were of 3.2% and 2.3% in the adult and pediatric setting, respectively (p=0.0022). In the adult setting, HCW more frequently reported exposure to COVID-19 patients without PPE (25% versus 15%, p=0.046). Report of contacts with children attending out-of-home care facilities dramatically decreased over the study period. Conclusion Universal masking, reinforcement of hand hygiene, and PPE with medical masks for patients’ care allowed protection of HCW and containment of the outbreak. Residual transmissions were related to persistent exposures with undiagnosed patients or colleagues and not to contacts with children attending out-of-home care facilities.
Collapse
Affiliation(s)
- Adrien Contejean
- Université de Paris, Faculté de Médecine, Paris, France.,Equipe Mobile d'Infectiologie, Assistance Publique-Hôpitaux de Paris, APHP.CUP, Hôpital Cochin, Paris, France
| | - Jérémie Leporrier
- Service de maladies infectieuses et tropicales, Assistance Publique-Hôpitaux de Paris, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France
| | - Etienne Canouï
- Equipe Mobile d'Infectiologie, Assistance Publique-Hôpitaux de Paris, APHP.CUP, Hôpital Cochin, Paris, France
| | - Fanny Alby-Laurent
- Université de Paris, Faculté de Médecine, Paris, France.,Service de maladies infectieuses et tropicales, Assistance Publique-Hôpitaux de Paris, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France
| | - Emmanuel Lafont
- Université de Paris, Faculté de Médecine, Paris, France.,Service de maladies infectieuses et tropicales, Assistance Publique-Hôpitaux de Paris, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France
| | - Lauren Beaudeau
- Equipe Mobile d'Infectiologie, Assistance Publique-Hôpitaux de Paris, APHP.CUP, Hôpital Cochin, Paris, France
| | - Perrine Parize
- Service de maladies infectieuses et tropicales, Assistance Publique-Hôpitaux de Paris, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France
| | - Fabienne Lecieux
- Service de santé au travail, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | - Agnès Greffet
- Service de santé au travail, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants malades, Paris, France
| | - Gérard Chéron
- Université de Paris, Faculté de Médecine, Paris, France.,Service d'urgences pédiatriques, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants malades, Paris, France
| | - Rémy Gauzit
- Equipe Mobile d'Infectiologie, Assistance Publique-Hôpitaux de Paris, APHP.CUP, Hôpital Cochin, Paris, France
| | - Jacques Fourgeaud
- Laboratoire de virologie, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants malades, Paris, France.,EHU 7328 PACT, Institut Imagine, Université de Paris, Faculté de Médecine, Paris, France
| | - Anne-Sophie L'Honneur
- Service de virologie, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | - Jean-Marc Tréluyer
- Département de soins intensifs pédiatriques, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants malades, Paris, France.,Pharmacology and Drug Evaluation in Children and Pregnant Women EA7323, Université de Paris, Faculté de Médecine, Paris, France.,Département de pharmacologie clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | - Caroline Charlier
- Université de Paris, Faculté de Médecine, Paris, France.,Service de maladies infectieuses et tropicales, Assistance Publique-Hôpitaux de Paris, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France
| | - Anne Casetta
- Equipe opérationnelle d'hygiène hospitalière, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | - Pierre Frange
- EHU 7328 PACT, Institut Imagine, Université de Paris, Faculté de Médecine, Paris, France.,Laboratoire de microbiologie clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants malades, Paris, France
| | - Marianne Leruez-Ville
- Laboratoire de virologie, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants malades, Paris, France.,EHU 7328 PACT, Institut Imagine, Université de Paris, Faculté de Médecine, Paris, France
| | - Flore Rozenberg
- Université de Paris, Faculté de Médecine, Paris, France.,Service de virologie, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | - Olivier Lortholary
- Université de Paris, Faculté de Médecine, Paris, France.,Service de maladies infectieuses et tropicales, Assistance Publique-Hôpitaux de Paris, IHU Imagine, Hôpital Necker-Enfants malades, Paris, France.,Institut Pasteur, Molecular Mycology Unit, National Reference Centre for Invasive Mycoses and Antifungals, CNRS UMR 2000, Paris, France
| | - Solen Kernéis
- Equipe Mobile d'Infectiologie, Assistance Publique-Hôpitaux de Paris, APHP.CUP, Hôpital Cochin, Paris, France.,Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France.,Université de Paris, INSERM, IAME, Paris, France
| |
Collapse
|
45
|
Chavarot N, Burger C, Aguilar C, Scemla A, Sberro-Soussan R, Amrouche L, Leruez-Ville M, Martinez F, Legendre C, Anglicheau D, Zuber J. Ig-responsive relapsing inflammatory syndrome following COVID-19 in a kidney transplant recipient. Kidney Int 2021; 99:767-768. [PMID: 33518372 PMCID: PMC7826029 DOI: 10.1016/j.kint.2020.12.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Accepted: 12/28/2020] [Indexed: 11/17/2022]
Affiliation(s)
- Nathalie Chavarot
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France.
| | - Carole Burger
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Claire Aguilar
- Université de Paris, Paris, France; Department of Infectious Diseases and Tropical Medicine, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Anne Scemla
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Rebecca Sberro-Soussan
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Lucile Amrouche
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Marianne Leruez-Ville
- Université de Paris, Paris, France; Department of Virology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Frank Martinez
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Christophe Legendre
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Dany Anglicheau
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| | - Julien Zuber
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, Paris, France
| |
Collapse
|
46
|
Leruez-Ville M, Ren S, Magny JF, Jacquemard F, Couderc S, Garcia P, Maillotte AM, Benard M, Pinquier D, Minodier P, Astruc D, Patural H, Ugolin M, Parat S, Guillois B, Garenne A, Parodi M, Bussières L, Stirnemann J, Sonigo P, Millischer AE, Ville Y. Accuracy of prenatal ultrasound screening to identify fetuses infected by cytomegalovirus which will develop severe long-term sequelae. Ultrasound Obstet Gynecol 2021; 57:97-104. [PMID: 32339337 DOI: 10.1002/uog.22056] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 04/06/2020] [Accepted: 04/12/2020] [Indexed: 06/11/2023]
Abstract
OBJECTIVES To compare the ability of detailed routine ultrasound examination, performed without knowledge of maternal serology and fetal status, with that of targeted prenatal imaging performed in prenatal diagnostic units in cases of known fetal infection to identify cytomegalovirus (CMV)-infected fetuses that will develop long-term sequelae. METHODS All prenatal imaging reports were collected for 255 children with congenital CMV in a registered cohort between 2013 and 2017 (NCT01923636). All women had undergone detailed routine fetal ultrasound examination at 20-24 and 30-34 weeks as part of routine antenatal care. All cases of known fetal CMV infection had also undergone targeted prenatal ultrasound examination. Postnatal structured follow-up for up to 48 months of age involved clinical, audiological and neurological assessment, including Brunet-Lezine scoring. Long-term sequelae (> 12 months) were considered to be mild in cases with isolated unilateral hearing loss and/or vestibular disorders, and severe in cases with bilateral hearing loss and/or neurological sequelae. All imaging reports were analyzed retrospectively with the knowledge of congenital CMV infection, searching for reference to findings that were, or could have been, related to fetal infection. Findings were analyzed in relation to whether the cases were diagnosed with CMV in utero or only postnatally. RESULTS There were 237 children with complete follow-up data (> 12 months), for a median of 24 (range, 12-48) months. Of these, 30% (71/237) were diagnosed with CMV prenatally and 70% (166/237) were diagnosed within 3 weeks after birth. 72.5% (29/40) of children with long-term sequelae, including 74% (14/19) with severe long-term sequelae, were not identified in the prenatal period. Among those diagnosed prenatally, the sensitivity of prenatal imaging for predicting long-term sequelae and severe long-term sequelae was 91% and 100%, respectively, while, in the group diagnosed only postnatally, non-specific infection-related ultrasound findings had been reported without raising suspicion in 48% of cases with long-term sequelae and 64% of those with severe long-term sequelae. CONCLUSIONS Routine detailed ultrasound examination in pregnancy is not an appropriate screening tool for congenital CMV infection that leads to long-term sequelae, in contrast with the high performance of targeted prenatal imaging in known cases of fetal infection. The non-specific nature of ultrasound features of CMV and their evolution, and a lack of awareness of caregivers about congenital CMV, are likely explanations. Awareness of the sonologist regarding congenital CMV and knowledge of the maternal serological status in the first trimester seem key to the performance of prenatal ultrasound. Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- M Leruez-Ville
- EA 73-28, Paris Descartes University, Sorbonne Paris Cité, Paris, France
- AP-HP, Hospital Necker-E.M., Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections, Paris, France
| | - S Ren
- EA 73-28, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - J-F Magny
- EA 73-28, Paris Descartes University, Sorbonne Paris Cité, Paris, France
- AP-HP, Hospital Necker-E.M., Neonatal Intensive Care Unit, Paris, France
| | - F Jacquemard
- American Hospital of Paris, Prenatal Diagnostic Unit, Neuilly, France
| | - S Couderc
- Hospital Intercommunal Poissy-Saint Germain, Maternity, Poissy, France
| | - P Garcia
- AP-HM, Hospital La Conception, Neonatology and Intensive Care Department, Marseille, France
| | - A-M Maillotte
- CHU Nice, Hospital L'Archet, Neonatal Intensive Care Unit, Nice, France
| | - M Benard
- Toulouse University Hospital, Department of Neonatology, Toulouse, France
| | - D Pinquier
- Rouen University Hospital, Department of Neonatology, Rouen, France
| | - P Minodier
- AP-HM, Hospital Nord, Emergency Care Department, Marseille, France
| | - D Astruc
- Strasbourg University Hospital, Department of Neonatology, Strasbourg, France
| | - H Patural
- University Hospital, Neonatal Intensive Care Unit, Saint-Etienne, France
| | - M Ugolin
- CHU Rennes and CIC1414, Pediatric Department, Neonatology, Rennes, France
| | - S Parat
- AP-HP, Hospital Cochin, Maternity, Paris, France
| | - B Guillois
- CHU de Caen, Department of Neonatology, Caen, France
- Université Caen Normandie, Medical School, Caen, France
| | - A Garenne
- CHRU Brest, Neonatal and Pediatric Intensive Care Unit, Brest, France
| | - M Parodi
- AP-HP, Hospital Necker-E.M., Otology Department, Paris, France
| | - L Bussières
- EA 73-28, Paris Descartes University, Sorbonne Paris Cité, Paris, France
- AP-HP, Hospital Necker-E.M., Clinical Research Unit, Paris, France
| | - J Stirnemann
- EA 73-28, Paris Descartes University, Sorbonne Paris Cité, Paris, France
- AP-HP, Hospital Necker-E.M., Maternity, Paris, France
| | - P Sonigo
- AP-HP, Hospital Necker-E.M., Radiology Department, Paris, France
| | - A E Millischer
- AP-HP, Hospital Necker-E.M., Radiology Department, Paris, France
| | - Y Ville
- EA 73-28, Paris Descartes University, Sorbonne Paris Cité, Paris, France
- AP-HP, Hospital Necker-E.M., Maternity, Paris, France
| |
Collapse
|
47
|
Toubiana J, Levy C, Allali S, Jung C, Leruez-Ville M, Varon E, Bajolle F, Ouldali N, Chareyre J, Béchet S, Elbez A, Casanova JL, Chalumeau M, Cohen R, Cohen JF. Association between SARS-CoV-2 infection and Kawasaki-like multisystem inflammatory syndrome: a retrospective matched case-control study, Paris, France, April to May 2020. ACTA ACUST UNITED AC 2020; 25. [PMID: 33272357 PMCID: PMC7716402 DOI: 10.2807/1560-7917.es.2020.25.48.2001813] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
We assessed the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and Kawasaki disease (KD)-like multisystem inflammatory syndrome in a retrospective case–control study in France. RT-PCR and serological tests revealed SARS-CoV-2 infection in 17/23 cases vs 11/102 controls (matched odds ratio: 26.4; 95% confidence interval: 6.0–116.9), indicating strong association between SARS-CoV-2 infection and KD-like illness. Clinicians should keep a high level of suspicion for KD-like illness during the COVID-19 pandemic.
Collapse
Affiliation(s)
- Julie Toubiana
- Institut Pasteur, Biodiversity and Epidemiology of Bacterial Pathogens, Paris, France.,Department of General Pediatrics and Pediatric Infectious Diseases, Necker-Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France
| | - Corinne Levy
- Université Paris Est, IMRB-GRC GEMINI, Créteil, France.,ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France.,GPIP, Groupe de Pathologie Infectieuse Pédiatrique, Paris, France.,Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Créteil, Créteil, France.,AFPA, Association Française de Pédiatrie Ambulatoire, Saint-Germain-en-Laye, France
| | - Slimane Allali
- Department of General Pediatrics and Pediatric Infectious Diseases, Necker-Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France
| | - Camille Jung
- Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Créteil, Créteil, France.,Université Paris Est, IMRB-GRC GEMINI, Créteil, France
| | - Marianne Leruez-Ville
- Virology laboratory, Necker-Enfants Malades University Hospital, AP-HP, EA 7328, Université de Paris, Paris, France
| | - Emmanuelle Varon
- Laboratoire de Microbiologie, Centre Hospitalier Intercommunal de Créteil, Créteil, France.,GPIP, Groupe de Pathologie Infectieuse Pédiatrique, Paris, France.,Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Créteil, Créteil, France.,Université Paris Est, IMRB-GRC GEMINI, Créteil, France
| | - Fanny Bajolle
- M3C-Necker-Enfants Malades University Hospital, AP-HP, Université de Paris, Paris, France
| | - Naim Ouldali
- Unité d'épidémiologie clinique, AP-HP, Hôpital Robert Debré, ECEVE INSERM UMR 1123, Paris, France.,GPIP, Groupe de Pathologie Infectieuse Pédiatrique, Paris, France.,ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France
| | - Judith Chareyre
- Pediatric Intensive Care Unit, Necker-Enfants Malades University Hospital, AP-HP, Université de Paris, Paris, France
| | - Stephane Béchet
- ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France
| | - Annie Elbez
- AFPA, Association Française de Pédiatrie Ambulatoire, Saint-Germain-en-Laye, France.,ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France
| | - Jean-Laurent Casanova
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, Howard Hughes Medical Institute, New York, United States.,Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Imagine Institute, Pediatric Hematology and Immunology Unit, Necker-Enfants Malades University Hospital, Université de Paris, Paris, France
| | - Martin Chalumeau
- Université de Paris, Centre of Research in Epidemiology and Statistics - CRESS, INSERM, F-75004 Paris, France.,Department of General Pediatrics and Pediatric Infectious Diseases, Necker-Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France
| | - Robert Cohen
- GPIP, Groupe de Pathologie Infectieuse Pédiatrique, Paris, France.,AFPA, Association Française de Pédiatrie Ambulatoire, Saint-Germain-en-Laye, France.,Université Paris Est, IMRB-GRC GEMINI, Créteil, France.,Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Créteil, Créteil, France.,Unité Court Séjour, Petits nourrissons, Service de Néonatalogie, Centre Hospitalier Intercommunal de Créteil, Créteil, France.,ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France
| | - Jérémie F Cohen
- Université de Paris, Centre of Research in Epidemiology and Statistics - CRESS, INSERM, F-75004 Paris, France.,Department of General Pediatrics and Pediatric Infectious Diseases, Necker-Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France
| |
Collapse
|
48
|
Faure-Bardon V, Magny JF, Parodi M, Couderc S, Garcia P, Maillotte AM, Benard M, Pinquier D, Astruc D, Patural H, Pladys P, Parat S, Guillois B, Garenne A, Bussières L, Guilleminot T, Stirnemann J, Ghout I, Ville Y, Leruez-Ville M. Sequelae of Congenital Cytomegalovirus Following Maternal Primary Infections Are Limited to Those Acquired in the First Trimester of Pregnancy. Clin Infect Dis 2020; 69:1526-1532. [PMID: 30596974 DOI: 10.1093/cid/ciy1128] [Citation(s) in RCA: 101] [Impact Index Per Article: 25.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Accepted: 12/27/2018] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND The known relationship between the gestational age at maternal primary infection an the outcome of congenital CMV is based on small, retrospective studies conducted between 1980 and 2011. They reported that 32% and 15% of cases had sequelae following a maternal primary infection in the first and second or the third trimester, respectively. We aimed to revisit this relationship prospectively between 2011 and 2017, using accurate virological tools. METHODS We collected data on women with a primary infection and an infected child aged at least 1 year at the time of analysis. An accurate determination of the timing of the primary infection was based upon serial measurements of immunoglobulin (Ig) M and IgG and on IgG avidity in sera collected at each trimester. The case outcome was assessed according to a structured follow-up between birth and 48 months. RESULTS We included 255 women and their 260 fetuses/neonates. The dating of the maternal infection was prospective in 86% of cases and retrospective in 14%. At a median follow-up of 24 months, the proportion of sensorineural hearing loss and/or neurologic sequelae were 32.4% (95% confidence interval [CI] 23.72-42.09) after a maternal primary infection in the first trimester, 0 (95% CI 0-6.49) after an infection in the second trimester, and 0 (95% CI 0-11.95) after an infection in the third trimester (P < .0001). CONCLUSIONS These results suggest that a cytomegalovirus infection can be severe only when the virus hits the fetus in the embryonic or early fetal period. Recent guidelines recommend auditory follow-ups for at least 5 years for all infected children. This raises parental anxiety and generates significant costs. We suggest that auditory and specialized neurologic follow-ups may be recommended only in cases of a maternal infection in the first trimester.
Collapse
Affiliation(s)
- Valentine Faure-Bardon
- Equipe d'Accueil, Paris Descartes University, Sorbonne Paris CitéArchet, France.,Maternity, Hospital Necker-E.M, Paris, France
| | - Jean-François Magny
- Equipe d'Accueil, Paris Descartes University, Sorbonne Paris CitéArchet, France.,Neonatal Intensive Care Unit, Hospital Necker-E.M, France
| | - Marine Parodi
- Otology Department, Assistance Publique de Paris, Hospital Necker-E.M, France
| | - Sophie Couderc
- Maternity, Hospital Intercommunal Poissy-Saint Germain, Marseille, France
| | - Patricia Garcia
- Neonatology and Intensive Care Department, Assistance Publique de Marseille, Hospital La Conception, Marseille, France
| | - Anne-Marie Maillotte
- Neonatal Intensive Care Unit, Centre Hospitalier Universitaire Nice, Hospital L'Archet, Marseille, France
| | - Melinda Benard
- Department of Neonatalogy, Toulouse University Hospital, Saint-Etienne, France
| | - Didier Pinquier
- Department of Neonatalogy, Rouen University Hospital, Saint-Etienne, France
| | - Dominique Astruc
- Department of Neonatalogy, Strasbourg University Hospital, Saint-Etienne, France
| | - Hugues Patural
- Neonatal Intensive Care Unit, University Hospital, Saint-Etienne, France
| | - Patrick Pladys
- Pediatric Department, Neonatology, Centre Hospitalier Universitaire Rennes and Centre d'Investigation Clinique, France
| | - Sophie Parat
- Maternity, Assistance Publique Hopitaux de Paris (AP-HP), Hospital Cochin, France
| | - Bernard Guillois
- Department of Neonatalogy, Centre Hospitalier Universitaire de Caen, France.,Medical School, Université Caen Normandie, France
| | - Armelle Garenne
- Brest, Neonatal and Pediatric Intensive Care Unit, Centre Hospitalier Régional Universitaire, France
| | - Laurence Bussières
- Equipe d'Accueil, Paris Descartes University, Sorbonne Paris CitéArchet, France.,Clinical Research Unit, AP-HP, Hospital Necker-E.M., France
| | - Tiffany Guilleminot
- Equipe d'Accueil, Paris Descartes University, Sorbonne Paris CitéArchet, France.,Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections, AP-HP, Hospital Necker-E.M., France
| | - Julien Stirnemann
- Equipe d'Accueil, Paris Descartes University, Sorbonne Paris CitéArchet, France.,Maternity, Hospital Necker-E.M, Paris, France
| | - Idir Ghout
- Unité de Recherche Clinique et Département de Santé Publique, AP-HP, Hôpital Ambroise Paré, Boulogne, France.,University Versaille-Saint-Quentin, Unité Mixte de recherche S, Université Versailles St-Quentin-en-Yvelines, Montigny, France
| | - Yves Ville
- Equipe d'Accueil, Paris Descartes University, Sorbonne Paris CitéArchet, France.,Maternity, Hospital Necker-E.M, Paris, France
| | - Marianne Leruez-Ville
- Equipe d'Accueil, Paris Descartes University, Sorbonne Paris CitéArchet, France.,Virology Laboratory, Reference Laboratory for Cytomegalovirus Infections, AP-HP, Hospital Necker-E.M., France
| |
Collapse
|
49
|
Affiliation(s)
- Marianne Leruez-Ville
- Virology Laboratory, National Reference Laboratory for Cytomegalovirus Infection, AP-HP, Hospital Necker Enfants-Malade, Paris 75015, France; EA 7328, Paris Descartes Université, Université de Paris, Paris, France.
| | - Yves Ville
- Fetal Medecine and Obstetrics, AP-HP, Hospital Necker Enfants-Malade, Paris 75015, France; EA 7328, Paris Descartes Université, Université de Paris, Paris, France
| |
Collapse
|
50
|
Contejean A, Leporrier J, Canouï E, Alby-Laurent F, Lafont E, Frange P, Leruez-Ville M, Rozenberg F, Lortholary O, Kernéis S. Évolution épidémique et déterminants de l’infection par le SARS-CoV-2 chez le personnel hospitalier : comparaison d’un centre adulte et d’un centre pédiatrique. Med Mal Infect 2020. [PMCID: PMC7441859 DOI: 10.1016/j.medmal.2020.06.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Introduction Matériels et méthodes Résultats Conclusion
Collapse
|